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Recent development of long-acting antiretroviral therapeutic regimens has opened a new 
chapter for HIV/AIDS management. Cabotegravir (CAB), as one of the very first long-
acting antiretroviral regimens, has drawn tremendous attention. However, the remaining 
challenges include suboptimal dosing intervals, large injection volume, injection site 
reactions, lack of tissue penetration, etc. As one of the pioneers in this field, our lab was 
successful in harnessing mononuclear phagocytes as “Trojan horses” for antiretroviral drug 
delivery and transportation to viral reservoirs. We proposed this targeted delivery strategy 
could address the limitations of current CAB formulation. To this end, we developed folic 
acid decorated CAB nanoformulation to target macrophages. The manufacturing scheme 
was optimized for formulation stability and reproducibility. Purification steps, previously 
considered necessary to remove excess receptor-competing targeted polymer, were 
eliminated for high drug loading and manufacturing ease. The resultant folic acid targeted 
CAB formulation exhibited enhanced macrophage uptake and improved pharmacokinetic 
profiles. To further improve CAB’s cellular retention, myristoylated CAB was synthesized 
and formulated into poloxamer 407 coated nanocrystal formulation, which exhibited 
markedly enhanced cellular retention, antiretroviral efficacy, pharmacokinetic and 
biodistribution profiles. The mechanism for prolonged half-life and enhance tissue 
penetration lies in the prompt mononuclear phagocytes entry and fast redistribution of the 
drug into reticuloendothelial system as observed in the injection sites and tissues. We 
	 III 
believe these improvements in formulation and medicinal chemistry unveil new 
opportunities for long-acting CAB formulation by readily addressing current existing 
limitations. These strategies, with simplified manufacturing schemes, hold translational 




First and foremost, I would like to give my sincere gratitude to my mentor Dr. Howard 
E Gendelman, who not only provided constant support to my research work, but also 
inspired me with his own hard working and enthusiasm in science during all these years. I 
am so thankful that he has been always available for my questions and generously shared 
his life wisdom for my education. From him, I learned how to become a real scientist with 
creative and critical thinking, integrity, and persistency. 
I would also like to sincerely thank my graduate supervisory committee members Drs. 
Tatiana K. Bronich, Joseph A. Vetro, JoEllyn M. McMillan, and Xinming Liu for their 
valuable guidance, suggestions, and encouragements throughout my Ph.D. training. I am 
grateful for the day-to-day expert advises from Dr. JoEllyn McMillan and Dr. Xinming 
Liu. I would like to thank Dr. Bronich and Dr. Vetro for their scientific training and 
valuable inputs on my research project and scientific fostering. I would also like to 
acknowledge our collaborators Dr. Larisa Poluektova and Dr. Santhi Gorantla for 
providing animal models and all the support I needed for the HIV restriction studies; Dr. 
Yazen Alnouti and Dr. Nagsen Gautam for UPLC/MS-MS method development and 
pharmacokinetic data analysis; Dr. R Lee Mosley for statistical analyses; Dr. Howard Fox, 
Benjamin Lamberty, Brenda Morsey, and Adam Szlachetka for the rhesus macaques 
pharmacokinetic study. 
I was fortunate to work with wonderful colleagues from Dr. Gendelman’s lab. I wish 
to especially thank Dr. Benson Edagwa for his guidance on chemistry and professional 
advices throughout this project. I would like to thank Drs. Prasanta Dash and Mariluz 
Arainga Ramirez for their guidance on the animal and biological studies; I would like to 
	 V 
thank Dr. Dongwei Guo and Dr. Pavan Puligujja for teaching me the formulation and 
biological assay techniques when I first joined the lab; Hang Su, Zhiyi Lin, James Hilaire, 
and Nathan Smith for their kind help on my experiments; Diana Palandri, Ted Kocher, and 
Bhagya Laxmi Dyavar Shetty for UPLC-MS/MS analysis. I would also like to thank Dr. 
Tianyuzi Li, Dr. Aditya Bade, Dr. Bhavesh Kevadiya, Dr. Saumya Nigam, Mary Banoub, 
Brady Sillman, Denise Cobb, Tanmay Kularni, Dhruvkumar Soni, Ibrahim Ibrahim, 
Brendan Ottemann, and Jonathan Herskovitz for their support during all these years.  
I would also like to express my sincere gratitude to the Chinese Scholarship Council 
and UNMC fellowship for the financial support in the past years. I would like to thank all 
administrative stuff at UNMC Graduate Studies, Department of Pharmaceutical Sciences, 
and Department of Pharmacology and Experimental Neuroscience to make my life easier. 
I would like to thank all the UNMC core facility staff and members in the UNMC animal 
facility for their extreme cooperation. 
Last but not the least, I would like to acknowledge my family and friends. Words failed 
me to express my gratitude to my parents, Guolin Ji and Ying Zhou, who are always 
supportive without any condition. I can be who I am only with their continuous 
encouragement. I owe a special thanks to Yuhong Yang for bearing me as roommate, and 
to Fang Yuan for offering me a place to draft this thesis. I would also like to thank Ke Ren, 
Dongwei Guo, Jian Zhang, Tianyuzi Li, Xiaobei Wang, Hang Su for their encouragements 
and lifelong friendship. Life is never easy, especially when pursuing the truth. Therefore, 
I appreciate everyone who has supported, encouraged and motivated me past several years.  
 
                                                                               
	 VI 
                                                                                                      Tian Zhou 
University of Nebraska Medical Center 






Table of Contents 
List of Figures .................................................................................................................. XI	
List of Tables ................................................................................................................ XIV	
List of Abbreviation ....................................................................................................... XV	
Chapter I ............................................................................................................................ 1	
1.1 HIV/AIDS Epidemic ............................................................................................... 2	
1.2 HIV Pathobiology ................................................................................................... 3	
1.3 Current HIV management ..................................................................................... 6	
1.3.1 Entry/fusion inhibitors ....................................................................................... 6	
1.3.2 Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ....................... 7	
1.3.3 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) ............................... 8	
1.3.4 Integrase strand transfer inhibitors (INSTIs) ..................................................... 8	
1.3.5 Protease inhibitors (PIs) ..................................................................................... 8	
1.3.6 Current management standards and challenges ................................................. 9	
1.4 Long-acting (LA) antiretroviral therapy (ART) ................................................ 10	
1.4.1 Challenges in LA ART development ............................................................... 11	
1.4.2 LA Cabotegravir (CAB) and rilpivirine (RPV) ............................................... 12	
1.4.3 Long-acting slow effective release antiretroviral therapy (LASER ART) ...... 14	
1.5 Scope and significance of current project ........................................................... 15	
1.6 References .............................................................................................................. 16	
Chapter II ........................................................................................................................ 26	
2.1 Abstract .................................................................................................................. 27	
2.2 Introduction ........................................................................................................... 27	
2.3 Materials and Methods ......................................................................................... 29	
	 VIII 
2.3.1 Materials .......................................................................................................... 29	
2.3.2 Size reduction by high-pressure homogenization ............................................ 30	
2.3.3 Formulation purification by differential centrifugation ................................... 31	
2.3.4 Formulation purification by tangential flow filtration (TFF) .......................... 31	
2.3.5 Physicochemical characterizations .................................................................. 31	
2.3.6 FA content detection ........................................................................................ 32	
2.3.7 FA NCAB monocyte-derived macrophages (MDM) uptake ........................... 32	
2.3.8 CAB concentration detection ........................................................................... 33	
2.3.9 PK determinations ............................................................................................ 33	
2.3.10 Ethics .............................................................................................................. 34	
2.4 Results .................................................................................................................... 34	
2.4.1 FA NCAB purification by differential centrifugation ..................................... 34	
2.4.2 FA NCAB preparation by TFF ........................................................................ 36	
2.4.3 Direct particle synthesis ................................................................................... 39	
2.4.4 PK evaluation ................................................................................................... 42	
2.4.5 Additives .......................................................................................................... 44	
2.5 Discussion .............................................................................................................. 47	
2.6 Conclusions ............................................................................................................ 51	
2.7 References .............................................................................................................. 51	
Chapter III ....................................................................................................................... 56	
3.1 Abstract .................................................................................................................. 57	
3.2 Introduction ........................................................................................................... 57	
3.3 Materials and Methods ......................................................................................... 59	
3.3.1 Materials .......................................................................................................... 59	
3.3.2 Myristoyl CAB (MCAB) synthesis ................................................................. 59	
3.3.3 Physicochemical characterizations of MCAB ................................................. 60	
3.3.4 Solubility test ................................................................................................... 61	
3.3.5 Half maximal inhibitory concentration (IC50) evaluation ................................ 61	
	 IX 
3.3.6 Nanoformulation preparation ........................................................................... 62	
3.3.7 Nanoformulation characterization ................................................................... 62	
3.3.8 Cell viability evaluation ................................................................................... 63	
3.3.9 MDM uptake and retention .............................................................................. 63	
3.3.10 Transmission electron microscopy (TEM) .................................................... 64	
3.3.11 Statistics ......................................................................................................... 64	
3.4 Results .................................................................................................................... 65	
3.4.1 Synthesis and structure confirmation of myristoylated CAB (MCAB) ........... 65	
3.4.2 MCAB crystal structure, solubility and antiretroviral activity ........................ 65	
3.4.3 Nanoformulated MCAB (NMCAB) ................................................................ 69	
3.4.4 MDM toxicity evaluation ................................................................................. 71	
3.4.5 MDM uptake and retention .............................................................................. 72	
3.4.6 In vitro antiretroviral activity ........................................................................... 74	
3.5 Discussion .............................................................................................................. 76	
3.6 Conclusions ............................................................................................................ 78	
3.7 References .............................................................................................................. 78	
Chapter IV ....................................................................................................................... 83	
4.1. Abstract ................................................................................................................. 84	
4.2. Introduction .......................................................................................................... 84	
4.3. Materials and Methods ........................................................................................ 86	
4.3.1 Materials .......................................................................................................... 86	
4.3.2 PK and BD of NMCAB in BALB/cJ mice ...................................................... 86	
4.3.3 Short-term PK and BD evaluation ................................................................... 87	
4.3.4 UPLC-MS/MS plasma and tissue drug quantitation ........................................ 87	
4.3.5 Injection depot evaluation by TEM ................................................................. 88	
4.3.6 Studies of viral restriction in HIV infected mice model .................................. 89	
4.3.7 Viral load and HIV RNA and DNA PCR determinations ............................... 89	
4.3.8 NMCAB PK in rhesus macaques ..................................................................... 90	
	 X 
4.3.9 Nanomedicine Production Plant GLP Facility Production of NMCAB .......... 90	
4.3.10 Statistics ......................................................................................................... 92	
4.3.11 Study approval ............................................................................................... 92	
4.4 result ....................................................................................................................... 93	
4.4.1 NMCAB PK and BD analysis in BALB/cJ mice ............................................. 93	
4.4.2 Short-term PK evaluation for drug depot ......................................................... 96	
4.4.3 Site of injection TEM analysis ......................................................................... 97	
4.4.4 Viral restriction evaluation .............................................................................. 99	
4.4.5 Tissue viral RNA and DNA evaluation ......................................................... 100	
4.4.6 Plasma and tissue drug concentrations .......................................................... 103	
4.4.7 Preliminary PK study in rhesus macaques ..................................................... 104	
4.5 Discussion ............................................................................................................ 108	
4.6 Conclusion ........................................................................................................... 110	
4.7 References ............................................................................................................ 110	
Chapter V ...................................................................................................................... 114	
5.1 Conclusions .......................................................................................................... 115	
5.2 Challenges and future directions ....................................................................... 117	
5.3 References ............................................................................................................ 118	
	
	 XI 
List of Figures 
Figure 1.1 HIV replication cycle ........................................................................................ 4	
Figure 1.2 Schematic diagram of the course of HIV-1 infection ....................................... 5	
Figure 1.3 Chemical structures of different categories phenotype antiretroviral drugs…..7 
Figure 1.4 Illustration of the impact of a missed oral dose or injection on plasma 
concentrations ........................................................................................................... 11	
Figure 2.1 Size reduction scheme for FA NCAB prepared with purification procedure. 30	
Figure 2.2 Post homogenization process scheme of FA NCAB purified by differential 
centrifugation ............................................................................................................ 35	
Figure 2.3 Evaluation of FA NCAB prepared by differential centrifugation .................. 36	
Figure 2.4 Manufacturing scheme for FA NCAB purified by TFF ................................. 37	
Figure 2.5 Evaluation of FA NCAB prepared by TFF. ................................................... 38	
Figure 2.6 1H-NMR of lyophilized FA NCAB formulation purified by TFF. ................. 39	
Figure 2.7 Manufacturing scheme of FA NCAB prepared by a direct method. .............. 40	
Figure 2.8 Evaluation of FA NCAB manufactured by direct method ............................. 41	
Figure 2.9 FA NCAB PK profiles in male BALB/cJ mice .............................................. 42	
Figure 2.10 FA NCAB biodistribution in BALB/cJ mice ............................................... 44	
Figure 2.11 Formulation additives and FA NCAB stability ............................................ 46	
Figure 2.12 FA NCAB uptake in MDM with or without glucose and mannitol ............. 47	
Figure 3.1 MCAB synthetic route .................................................................................... 60	
Figure 3.2 1H-NMR spectra of CAB and MCAB. ........................................................... 66	
Figure 3.3 FT-IR spectra of CAB and MCAB. ................................................................ 67	
Figure 3.4 XRD spectra of MCAB and CAB. ................................................................. 67	
	 XII 
Figure 3.5 Solubility of CAB and MCAB in water and 1-octanol .................................. 68	
Figure 3.6 Antiretroviral activities of CAB and MCAB in HIV-1ADA infected human 
MDM ........................................................................................................................ 68	
Figure 3.7 NMCAB preparation by high-pressure homogenization ................................ 69	
Figure 3.8 XRD analysis of lyophilized CAB LAP and NMCAB formulations. ............ 69	
Figure 3.9 SEM analysis of morphologies of NMCAB and CAB LAP .......................... 71	
Figure 3.10 NMCAB stability over 90 days ........................................................................ 71	
Figure 3.11 Toxicity evaluation in MDM ........................................................................ 72	
Figure 3.12 NMCAB uptake and retention in MDM ....................................................... 73	
Figure 3.13 Transmission electron microscopy (TEM) images of formulation-loaded 
MDM ........................................................................................................................ 74	
Figure 3.14 NMCAB antiretroviral efficacy .................................................................... 75	
Figure 4.1 NMCAB PK and BD study experimental timeline ........................................ 93	
Figure 4.2 NMCAB PK evaluation in BALB/cJ mice ..................................................... 94	
Figure 4.3 NMCAB biodistribution ................................................................................. 95	
Figure 4.4 NMCAB short-term PK and BD evaluation ................................................... 97	
Figure 4.5 Injection site depot analysis ............................................................................ 98	
Figure 4.6 Viral restriction of NMCAB compared to CAB LAP in hu-PBL reconstituted 
NSG mice ................................................................................................................ 100	
Figure 4.7 Tissues viral RNA DNA by semi-nested real time PCR at day 32 .............. 101	
Figure 4.8 HIV-1p24 staining for viral restriction study ............................................... 102	
Figure 4.9 Viral restriction study animal plasma and tissue CAB concentrations ........ 103	
	 XIII 
Figure 4.10 Correlation between plasma CAB concentrations and log10 plasma viral load 
on day 32 in drug treated mice. ............................................................................... 104	
Figure 4.11 NMCAB PK study in rhesus macaques ...................................................... 104	
  
	 XIV 
List of Tables 
Table 2.1 FA NCAB physicochemical properties ............................................................ 34	
Table 2.2 Non-compartmental PK analysis ...................................................................... 43	
Table 2.3 The effect of additives on FA NCAB stability ................................................. 45	
Table 3.1 Physicochemical properties of NMCAB, MCAB, and CAB LAP .................. 70	
Table 4.1 BALB/cJ mice noncompartmental PK analysis ............................................... 94	
Table 4.2 Rhesus macaque non-compartmental PK analysis ......................................... 105	
Table 4.3 Complete blood counts and metabolic panel of rhesus macaques administrated 




List of Abbreviation 
AIDS acquired immune deficiency syndrome  
HIV human immunodeficiency virus 
ART antiretroviral therapy  
NRTI nucleoside/nucleotide reverse transcriptase inhibitor 
NNRTI non-nucleoside reverse transcriptase inhibitor  
INSTI integrase strand transfer inhibitor 
PI protease inhibitor 
CNS central nervous system 
PK pharmacokinetics  
FDA Food and Drug Administration  
PrEP pre-exposure prophylaxis  
BD biodistribution  
PD pharmacodynamics  
LA long-acting  
API active pharmaceutical ingredient  
CAB cabotegravir  
RPV rilpivirine 
LASER ART long-acting slow effective release antiretroviral therapy 
	 XVI 
FA folic acid 
PA-IC90  protein-binding-adjusted 90% inhibitory concentration 
P407 poloxamer 407 
FA-P407 folic acid conjugated poloxamer 407 
FA NCAB folic acid decorated nanoformulated cabotegravir 
CAB LAP cabotegravir long-acting parenteral formulation 
DMSO dimethyl sulfoxide 
PEG polyethylene glycol 
DMEM Dulbecco’s Modified Eagle’s Medium 
HPLC high performance liquid chromatograph 
ACN acetonitrile 
TFF tangential flow filtration 
DV diavolume  
Deff effective diameter  
PdI polydispersity index  
DLS dynamic light scattering  
SEM scanning electron microscopy  
1H-NMR proton nuclear magnetic resonance  
MDM monocyte-derived macrophages 
	 XVII 
PBS phosphate-buffered saline  
UPLC ultra performance liquid chromatography  
MCAB myristoylated cabotegravir 
NMCAB nanoformulated myristoylated cabotegravir 
DIEA N,N-diisopropylethylamine 
DMF dimethylformamide 
CCK-8 cell counting kit-8 
FT-IR fourier transform infrared spectroscopy 
XRD X-ray diffraction  
IC50 half maximal inhibitory concentration  
MOI multiplicity of infection 
RT reverse transcriptase  
NCAB nanoformulated CAB  
TEM transmission electron microscopy  
SD standard deviation  
PFA paraformaldehyde  
DAB 3,3’-diaminobenzidine 
IS internal standard  
NSG NOD/SCID/IL2Rγc-/-  
	 XVIII 
PBL peripheral blood lymphocytes 
TCID50 50% tissue culture infectious dose  
EDTA ethylenediaminetetraacetic acid  
GLP Good Laboratory Practices  
SOP standard operating procedures  









1.1 HIV/AIDS Epidemic 
In 1981, a new disease known today as acquired immune deficiency syndrome (AIDS) 
was firstly reported among homosexual men in New York City and California [3]. The 
cause of the disease was later on identified as the human immunodeficiency virus (HIV) 
[4]. Since then, HIV has spread globally and became a major public health issue. So far, it 
has taken more than 35 million lives. In 2016, there were 1.0 million HIV caused deaths 
and 1.8 million new infected population. By the end of 2016, there were approximately 
36.7 million people living with HIV. African is the most affected region in where 25.6 
million people living with HIV in 2016 [5].  
HIV is transmitted through body fluids, including blood, semen, breast milk, vaginal 
fluids, and rectal fluids. Transmission can happen if these body fluids of an infected person 
directly contact with mucous membrane, damaged tissue, or directly injected into 
bloodstream. Having unprotected sex and sharing injection equipment with someone who 
has HIV are the major reason for HIV spreading. HIV can also be transmitted from mother 
to child during pregnancy, childbirth, or breastfeeding. 
Tremendous efforts have been made to better understand the devastating disease and 
to develop effective therapies. Nevertheless, despite all the remarkable progresses, HIV is 
still incurable. Fortunately, the development of antiretroviral drugs, which suppress viral 
replication and restore immune system function, has markedly reduced disease-associated 
morbidities and mortality, enabling a nearly normal life span and quality for infected 
people [6-8]. Nowadays, HIV is treated as a chronic disease. Lifelong treatment of 
combinational antiretroviral therapy is required to contain the disease. Nevertheless, drug 
resistance, chronic toxicities, and suboptimal patient adherence have impeded therapeutic 
	 3 
effectiveness. Therefore, it is imperative to develop improved therapeutics and prevention 
strategies to better manage HIV/AIDS and ultimately eliminate the disease. 
1.2 HIV Pathobiology 
HIV is a retrovirus with a highly organized structure. It has a roughly spherical structure 
with a diameter of 80 to 120 nm. The core of HIV virus is a conical capsid structure 
composed of the viral protein p24. The capsid encases 2 copies of single stranded RNA 
and 3 key enzymes: reverse transcriptase, integrase, and protease. The capsid helps to 
protect viral genome and to promote adsorption of HIV onto host cell surfaces. The core is 
encased in a lipid bilayer membrane derived from host cell membrane, in which a number 
of host cell proteins and viral specific glycoproteins transmembrane envelope glycoprotein 
gp41 and surface envelop glycoprotein gp120 are embedded.  
HIV must enter host cells and insert viral genome into host genome in order to replicate. 
Typically, it attaches to host cell membrane through interaction between gp120 and host 
cell CD4 receptor, which is expressed on helper T cells, monocytes, macrophages, 
dendritic cells, etc. Upon interaction, gp120 conformational change triggers its interaction 
with a co-receptor, either CXCR4 (X4) or CCR5 (R5). This subsequently triggers fusion 
peptide gp41 piercing host cell membrane and pulling host cell membrane and viral 
membrane together, after which viral capsid enters host cell cytoplasm and dissociates to 
release viral genome. After entering host cells, viral reverse transcriptase catalyzes the 
synthesis of double-stranded viral cDNA using viral RNA as template. Viral cDNA then 
inserts into host genome with the assistance of viral integrase. Transcription can happen 
using host cell transcription machinery with the help of the viral protein trans-activator of 
transcription (tat). The produced RNA can then be translated into structural and genomic 
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viral proteins (spliced transcripts) or become viral genomic RNA (unspliced transcripts). 
Translated viral proteins require viral protease cleavage to be fully functioning. Finally, 
newly formed viral RNA, functional proteins, and envelope and capsid proteins are 
assembled together within cellular vacuoles at cell membrane before budding from host 
cells surface to become infectious new virus (Figure 1.1). It is noteworthy that viral reverse 
transcriptase has high error prone that leads to genetic instability of HIV. Hence, various 
 
Figure 1.1 HIV replication cycle (Adapted from https://www.niaid.nih.gov) 
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HIV strains can be detected even within one infected individual. Also, The genetic 
instability also helps to alter pathogenicity and promote immune escape [9].  
A typical progression of HIV infection without any treatment is shown in Figure 1.2. 
After HIV transmission, primary infection happens within 2-6 weeks. This stage is 
characterized by high plasma viremia, low CD4 counts and absence of HIV antibodies. 40-
90% patients develop non-specific symptoms, including fever, lethargy, rash, headache, 
etc. As the development of cytotoxic CD8+ T cell response, viremia can be controlled 
temporarily, which leads to a clinic latent stage. During this stage, the patients show few 
symptoms except for lymphadenopathy. Yet, the disease still progresses due to active low 
levels of viral replication. This asymptomatic period can vary from 1 to 15 years depending 
on the HIV subtypes and patients’ status. As the depletion of CD4+ T cells and the viral 
evolution, eventually plasma viremia increases, and symptoms emerge. When blood CD4 
	
Figure 1.2 Schematic diagram of the course of HIV-1 infection. This diagram illustrates the 
relationship between HIV-1 virus load (red line) and CD4+ T-cell count (blue line) over time 
in a typical case of untreated HIV-1 infection. DC: dendritic cells. (Adapted from Sarah L. 
Rowland-Jones, Nature Reviews Immunology, Volume 3, April 2003, 343-348 [1].) 
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counts falls below 200 cells/mm3, patients’ immune system become extremely vulnerable 
to opportunistic infections and malignancies. This stage is called AIDS and is often 
associated with high morbidity.   
 1.3 Current HIV management 
So far, there is no cure for HIV infection. Antiretroviral therapy (ART) can suppress 
viral replication, and subsequently reduce morbidity and mortality [6-8, 10, 11]. There are 
more than 20 approved ART regimens in US of five main classes that act against various 
stages of viral replication. These include entry/fusion inhibitors, nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PIs). The 
chemical structures of phenotype antiretroviral drugs are shown in Figure 1.3. 
1.3.1 Entry/fusion inhibitors 
Entry/fusion inhibitors interfere with the ability of virus to bind on host cell surface 
and/or fuse with cell membrane. This is the only class of antiretroviral drugs that acts before 
the infection. There are now two approved drugs in this class: enfuvirtide and maraviroc.  
Enfuvirtide is a peptide homologous to a segment of the HR2 region of gp41. It binds to 
the HR1 region of gp41 and blocks the formation of the 6-helix bundle necessary for fusion 
[12]. It is the only antiretroviral drug that is given subcutaneously. Maraviroc is a CCR5 
antagonist that interferes with viral gp120 binding. It is the only antiretroviral drug that 
targets a host cell protein. It can only be used in CCR5-tropic HIV infections in 
combination with other regimens. 
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1.3.2 Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) 
Zidovudine was the very first approved antiretroviral drug (1987). It belongs to NRTI 
class. It is no longer commonly used because of high toxicities and has been substituted by 
newer agents that are safer and longer lasting. These include abacavir, emtricitabine, 
lamivudine, and tenofovir. NRTIs interfere with reverse transcriptase activity by 
competing with the natural substrates and incorporating into viral DNA to act as chain 
terminators in the synthesis of proviral DNA. NRTIs are usually paired to form “back bone” 
Figure 1.3 Chemical structures of different categories phenotype antiretroviral drugs 
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of ART. Mitochondrial toxicities is the major concern as NRTIs are capable of inhibiting 
mitochondrial DNA polymerase as well. 
1.3.3 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTIs do not incorporate into viral DNA, but instead directly bind to the 
hydrophobic pocket located close to catalytic domain of the reverse transcriptase enzyme. 
Efavirenz, rilpivirine, delavirdine,	etravirine, and nevirapine belong to this class. NNRTIs 
are commonly used in combination with tenofovir and emtricitabine and are effective in 
patients who have failed previous ART not containing an NNRTI. Central nervous system 
(CNS) symptoms are the most common adverse effects. 
1.3.4 Integrase strand transfer inhibitors (INSTIs) 
INSTIs inhibit the insertion of viral DNA into host genome by blocking the binding of 
the preintegration complex to host cell DNA. Dolutegravir, elvitegravir, and raltegravir are 
the three approved regimens in this class. INSTIs are generally well tolerated and are 
preferred regimen in combination with 2 NRTIs for naïve patient treatment. 
1.3.5 Protease inhibitors (PIs) 
PIs prevent cleavage of gag and gag–pol protein precursors into functional proteins, 
arresting maturation and thereby blocking the infectivity of nascent virions [13]. There are 
10 approved PIs including atazanavir, darunavir, lopinavir, etc. Most of PIs are combined 
with low-dose of ritonavir as a pharmacokinetic (PK) booster because ritonavir inhibits 
CYP3A4 that can slow down the metabolism of PIs.		
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1.3.6 Current management standards and challenges 
ART is recommended immediately after diagnosis for all HIV-infected patients 
regardless of CD4 counts. Because of high mutation rate of HIV and low genetic barrier 
for individual antiretroviral drug (except for dolutegravir), monotherapy is prone to induce 
drug resistance. Therefore, combinational antiretroviral drugs are required to increase the 
barrier of resistance. Two NRTIs plus a third regimen from one of the other classes is 
minimum standard treatment for naïve patients [14]. Treatment must be for lifetime as ART 
can only suppress viral replication, however, it cannot eradicate HIV virons. To ease the 
administration and improve patient adherence, single tablet regimens that required once 
daily dosing have been developed. ART has been proven to be effective preventing HIV 
infection as well.	In 2012, the United States Food and Drug Administration (FDA), for the 
first time, approved Truvada®, combination oral emtricitabine/tenofovir disoproxil 
fumarate (FTC/TDF), as pre-exposure prophylaxis (PrEP) for people at high-risk of HIV-
1 acquisition. In clinical trials, Truvada® has achieved 44 - 75% reduced risk of HIV 
acquisition among homosexual and heterosexual high-risk populations [15-17].  
Combinational ART is effective suppressing HIV replication. However, it has 
limitations in pharmacokinetics/biodistribution (PK/BD) and pharmacodynamics (PD) in 
that the drugs cannot reach effective concentration in all regions of the body. Tissues/cells 
with limited drug access become viral sanctuaries where virus can replicate unimpeded 
[18-20]. Issues of drug adherence, side effects, malabsorption syndromes, development of 
drug resistance, and long-term toxicities of ART have further jeopardized long-term 
treatment successes.  
	 10 
1.4 Long-acting (LA) antiretroviral therapy (ART)  
Adherence to ART regimens is vital for both HIV treatment and prevention. 
Nevertheless, for many reasons, including treatment fatigue, lack of financial and social 
support, co-existing mental symptoms, substrate abuse, etc., HIV patients and high-risk 
populations do not always adhere to prescription ART regimens. In PrEP study, lack of 
adherence to daily oral regimen has been observed correlating with less-than-ideal HIV 
protection [21]. Therefore, means that can improve ART adherence are in great need. An 
important milestone in recent years to improve ART adherence is LA ART [22, 23].  
Besides improve patient adherence, LA ART can maintain plasma drug concentration 
within the therapeutic window in a less fluctuating pattern. Traditional daily oral treatment 
can also maintain plasma drug level within the therapeutic window. Nevertheless, one 
missed dose could lead to sharp decline of plasma drug concentration to a sub-therapeutic 
concentration that increases the risk of drug resistance development. In contrast, LA 
regimen could provide less fluctuating plasma drug concentrations with slower decay. 
Therefore, even if the patients forgot to receive the dose, plasma drug concentration would 
not fall below therapeutic window right away (Figure 1.4) [2]. 
Changes in treatment patterns from oral daily to monthly or even less-frequent 
administration may also provide greater patient privacy and satisfaction [24, 25]. For PrEP, 
one major reason for lack of adherence has been noticed that healthy participants concerned 
about being mistakenly identified as HIV positive [26]. This problem can be addressed by 
LA ART. A survey conducted in 400 HIV-1 seropositive patients [27] purported that 
majority (74%) of patients would consider switching from current daily pill regimens to a 
weekly to monthly LA regimen if one was available. Patients’ interest increases as the 
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dosing interval prolongs that 61% with weekly dosing, 72% every 2 weekly, and 84% 
monthly.  
1.4.1 Challenges in LA ART development 
One challenge for LA ART development is the dose limitation, as LA formulations are 
expected to contain drugs for weeks or even months. For example, abacavir is dosed orally 
every day at 600 mg. To make a LA formulation for monthly administration, theoretically, 
one has to encapsulate 18 g abacavir in a feasible volume (< 5 mL) for injection, which is 
technically not possible. Therefore, drug candidates that can be developed as LA ART must 
be highly potent with low daily dosage. 
	
Figure 1.4 Illustration of the impact of a missed oral dose or injection on plasma 
concentrations. The dashed black line represents sub-therapeutic concentrations with an 
increased risk for drug resistance. LAP formulations maintain concentrations necessary for 
viral suppression following a missed injection, whereas missed oral doses result in sub-
therapeutic concentrations and are at a greater risk for drug resistance. (Adapted from Magali 
B. Hickey, et al., Curr Opin Infect Dis. 2015 Dec;28 (6):603-610 [2] ) 
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For LA regimens, the most commonly used formulations are oil based formulation and 
drug crystals suspended in aqueous solution. Oil based formulation is composed of 
insoluble active pharmaceutical ingredient (API) and oils, for example sesame seed oil, as 
solvent. The first generation of LAP antipsychotic drugs, such as haloperidol decanoate 
and fluphenazine decanoate are of this kind [28]. However, it is no longer widely used 
because of high excipient content. Drug suspensions are more wildly used because it allows 
higher drug loading.  In order to be developed as drug crystal suspensions, APIs must have 
low aqueous solubility, which rules out all NRTIs and maraviroc [2]. In addition, the 
clearance of the ART candidates must be relatively slow so that the sustained released drug 
from the depot can reach therapeutic concentration before being eliminated. In addition, 
administer route change from oral to intramuscular or subcutaneous injection may affect 
API absorption, distribution, and metabolism. For example, NRTIs are usually prodrugs, 
the conversion rate of the prodrugs into their active forms may differ due to the 
administration route change. Therefore, dosage must be adjusted accordingly. Because all 
above-mentioned challenges in the development of LA ART, majority of current available 
antiretroviral drugs are not suitable to be redeveloped as LA regimens. 
1.4.2 LA Cabotegravir (CAB) and rilpivirine (RPV) 
Cabotegravir (CAB) plus rilpivirine (RPV) is the very first combinational LA ART in 
final development. CAB is a novel INSTI and a structural analogue of dolutegravir. RPV 
is a new generation NNRTI, and is effective against traditional NNRTI-resistant HIV-1 
[29]. Both CAB and RPV are highly potent with low aqueous solubility allowing them to 
be formulated into 200 mg/mL or 300 mg/mL suspensions via milling process [30, 31]. 
After intramuscular injection, because of the low aqueous solubility, slow dissolution of 
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the particles from the site of injections would provide sustainable plasma drug 
concentrations for extended period of time. 
In a phase II b study (LATTE-2; NCT02120352), combination of LA CAB and RPV 
formulations has demonstrated comparable antiretroviral activity to daily oral three-drug 
combinations for maintenance therapy [32]. Naïve patients were given oral 30 mg CAB plus 
abacavir-lamivudine once daily for 20 weeks to achieve viral suppression (plasma HIV 
RNA < 50 copies per mL), and then randomly assigned into intramuscular LA CAB plus 
RPV at 4-week intervals (LA CAB 400 mg plus RPV 600 mg; two 2 mL injections) or 8-
week intervals (LA CAB 600 mg plus RPV 900 mg; two 3 mL injections) or continued 
oral CAB plus abacavir-lamivudine. 96 weeks after switching to maintenance regimens, 
the viral suppression rate was 84% in the oral treatment group, 87% in the 4-week LA 
treatment group, and 94% in the 8-week LA treatment group, respectively. Patient 
satisfaction was scored higher in LA ART treated patients, especially 8-week treatment 
group. ≥ 99% of the patients receiving LA ART reported that they would be highly satisfied 
to continue LA regimen, while only 78% of the patients receiving oral regimen would elect 
to continue on oral dosing. A phase III clinical trial (NCT03299049) has been initiated to 
further evaluate the efficacy, safety and tolerability in a larger patient population. 
LA CAB and RPV are both being tested as PrEP regimen [33, 34]. PK data indicated 
that monthly to bimonthly injection intervals are achievable. However, for prevention 
purpose, longer dosing interval would be favorable. In addition, the most commonly 
reported side effect for both LA CAB and RPV is the injection site reactions associated 
with the high injection volumes. Taking together, with current promising profiles of LA 
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CAB and RPV, their broader application can be realized with means to further extend 
dosing intervals and reduce injection volumes.  
1.4.3 Long-acting slow effective release antiretroviral therapy (LASER ART) 
To further improve upon LA ART delivery, our laboratory recently developed cell 
targeted long-acting slow effective release ART (LASER ART). [35-38].  Previously studies 
have demonstrated that LASER ART offers prolonged half-lives, improved efficacy, PK, 
BD, and antiretroviral activities beyond native drugs [35, 36, 39, 40]. Cellular endosomal 
compartments are proved to be the storage for LASER ART in macrophages [41].  
Like CD4+ T cells, macrophages are considered as the early target for HIV viruses as 
they express CD4 receptors and CCR5 co-receptors [42-44]. They are less sensitive to 
cytopathic effects therefore can harbor the viruses for longer period of time [45]. In 
addition, macrophage turnover is slow. For example, brain microglial cells can survive for 
years. All these features make macrophages perfect reservoirs for HIV viruses [46]. 
Therefore, ART delivery into macrophages is critical for successful viral suppression. 
Taking the advantages of its phagocytic nature, our lab has been using macrophages as 
“Trojan Horse” for ART delivery. Delivering antiretroviral drugs into macrophages can 
not only better control viral replication, but also offers several advantages upon traditional 
ART. First and for most, macrophages are highly mobile that they can be recruited to the 
site of infection and inflammation [35]. This way, antiretroviral drugs can access tissue 
reservoirs, such as brain and lymphoid tissues that traditional ART may not reach.  Second, 
once engulfing drug crystals, macrophages can serve as a drug depot and slowly release 
the cargo. This can provide the advantage of sustained delivery, and ultimately extend 
apparent half-life and reduce acute toxicities related to the high peak plasma drug 
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concentration. Lastly, macrophages have high drug loading capacity that can harbor large 
amount of ART. If the release is controlled properly, this could ultimately reduce the 
dosing frequency.  
One means to achieve macrophage targeting is by creating ligand-targeted 
nanoparticles, for example, folic acid (FA) decorated nanoparticles [36, 37]. Chemical 
modification is another important tool for LASER ART development. As mentioned above, 
not all antiretroviral drugs are suitable for LA formulation development due to their 
intrinsic properties. Chemical modifications introducing cleavable moieties that improve 
hydrophobicity and lipophilicity without reducing the activities of the compounds, can 
transform antiretroviral drugs into LA compatible form [47, 48]. 
1.5 Scope and significance of current project  
Current study focuses on the development of next generation of CAB LAP.  CAB, as 
mentioned above, is a novel INSTI with low aqueous solubility, high melting point, high 
potency, long half-life, and slow metabolic clearance [30, 49]. These properties enable 
CAB to be formulated in a 200-mg/mL suspension (CAB LAP) and administered 
intramuscularly monthly or even less-frequently [32, 50]. An additional benefit rests in that 
CAB is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, 
with low potential to interact with other antiretroviral drugs [30, 51]. CAB LAP has also 
proven to be highly protective against rectal, vaginal, and intravenous SHIV transmission 
in non-human primates [52-55], and has been advanced into clinical trials for HIV 
prevention (NCT02720094). Despite such promising drug profiles, dosing pattern has 
limitations. Specifically, split injections given in 2 mL volumes are required to achieve 
800-mg doses, leading to treatment cessations because of the intolerable injection site 
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reactions [32, 33]. However, even with the high injection volumes, the maximal dosing 
interval is only 8 weeks. Recently in a phase 2a study investigating safety and tolerability 
of CAB LAP in HIV-uninfected men (ECLAIR; NCT02076178) [33], 800 mg doses every 
12 weeks was selected based on previous clinical studies [50, 56], aiming to maintain 
plasma CAB concentrations above 4 times protein-binding-adjusted 90% inhibitory 
concentration (4× PA-IC90, 660 ng/mL), a concentration demonstrated to be protective 
against new infections in macaques [52-55]. However, two-thirds of participants had faster 
than anticipated drug absorption from the injection site leading to plasma drug 
concentrations below targeted concentration of 4× PA-IC90 at 12 weeks. Therefore, follow 
up studies to HPTN 083 (a PrEP study) in HIV-uninfected cisgender men and transgender 
women) will require shortened dosing intervals (600 mg in 3 mL injection volumes every 
8 weeks) to achieve effective protection with relevant antiretroviral plasma drug 
concentrations. Taken together, a means to extend the dose interval beyond 12 weeks and 
reduce injection volumes could bring broader usage to such regimens [57]. 
Current study addresses above problems using various strategies including ligand-
targeted nanoparticles and prodrugs. The manufacture processes were optimized and 
simplified for translational purpose.  
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Optimizing the preparation and stability of folic 




While the therapeutic potential for LA ART is undeniable, optimal restriction of HIV 
infection made by drug penetration into infectious cell and tissue reservoirs has not yet 
been fully realized. Ligand-targeted nanoformulated LA ART could provide a means to 
optimize drug delivery to viral growth sites. However, an obstacle to translate such 
decorated ART rests in optimizing formulation preparation. This may also affect 
production reproducibility related to targeting ligand incorporation and presentation onto 
the nanoparticles. To this end, our laboratory developed a simplified, reproducible and 
scalable manufacture process for FA decorated nanoformulated ART for macrophage 
targeting. We now demonstrate that this can be achieved with CAB nanocrystals. The 
manufacturing process results in stable nanoparticles with high drug loading and 
reproducible monocyte-macrophage targeting. The scheme is superior over previous 
production methods based on particle preparation simplicity and reproducibility. Direct 
manufacturing of FA nanoparticles provides a path toward large-scale clinical grade 
manufacturing of cell-targeted LA ART.  
2.2 Introduction 
LA ART has generated considerable interest in the treatment and prevention of HIV 
infection. After parenteral injection, LA ART demonstrated effective plasma drug 
concentrations for months overcoming regimen adherence issues amongst HIV infected 
people [1]. As mentioned in chapter I, Combinational LA CAB and RPV is the very first 
LA ART regimen demonstrating comparable efficacy and safety to daily oral three drug 
regimens [2]. CAB and RPV are highly potent medicines with low aqueous solubility, 
allowing both to be formulated into 200 or 300 mg/mL suspensions by wet-milling [3, 4]. 
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This formulation strategy produces pure nanosized drug crystals stabilized by surfactants 
with high drug loading. Nevertheless, two injections of 2 or 3 mL volumes are required to 
achieve monthly or bimonthly injections. Injection site reactions are the most common 
adverse event and a reason for patient withdrawal in clinical trials [2, 5, 6]. Variant PK 
profiles, and lack of penetration into mucosal and viral reservoir tissues are other 
limitations that could affect long-term therapeutic outcomes and emergence of viral 
resistance [5]. Delivery ART into macrophages can address above issues, and one means 
to achieve macrophage targeting is by creating ligand-targeted nanoparticles. By attaching 
ligands that bind to specific cell receptors, targeted nanoparticles can better reach and 
release therapeutic agents at the disease site. In this case, FA can be used as the targeting 
ligand to target folate receptor beta expressed on the surface of activated macrophages [7]. 
Indeed, previous studies from our group have demonstrated that FA decorated 
nanoparticles can improve PK profiles and antiretroviral activity of ART [8, 9]. FA was 
covalently conjugated on the hydrophilic termini of amphiphilic poloxamer 407 (P407), 
which serves as a stabilizer to prevent drug crystals from agglomeration. After high-
pressure homogenization, FA conjugated P407 (FA-P407) coats the nanosized drug 
crystals presenting FA on the outer surface. Excessive FA-P407 was removed by 
differential centrifugation, which is essential for targeting activity as unbounded FA-P407 
competes FA decorated nanoparticle for receptor binding [8]. Nevertheless, high-speed 
centrifugation may affect particle aggregation and limit resuspension and large-scale 
production. In fact, other purification methods, such as filtration, dialysis and 
chromatography, are also tedious and show limitations in the preparation of nanoparticles 
[10]. 
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Therefore, we developed a simplified, scalable and reproducible production scheme for 
macrophage-targeted CAB nanoparticles to abrogate purification processes. The resultant 
FA decorated CAB nanoformulation (FA NCAB) demonstrated high particle integrity and 
drug loading with potential for large scale production. Notably, the process can be adapted 
to other ligand-targeted delivery systems and thus be of broad utility in the production of 
ligand-targeted nanocrystals. 
2.3 Materials and Methods 
2.3.1 Materials 
CAB and CAB long-acting parenteral (CAB LAP) formulation were given as a gift 
from ViiV Healthcare (Research Triangle Park, NC, USA). P407, poloxamer 188 (P188), 
dimethyl sulfoxide (DMSO), polyethylene glycol (PEG) 2000, PEG 3350, PEG 4600, 
histidine, sodium carboxymethyl cellulose, sucrose, dextrose, trehalose, glucose, and 
mannitol were purchased from Sigma-Aldrich (St. Louis, MO, USA). FA conjugated P407 
(FA-P407) was synthesized as previously reported [8]. Dulbecco’s Modified Eagle’s 
Medium (DMEM) was purchased from Corning Life Sciences (Tewksbury, MA). Heat-
inactivated pooled human serum was obtained from Innovative Biologics (Herndon, VA). 
Gentamicin, high performance liquid chromatograph (HPLC) grade acetonitrile (ACN), 
HPLC grade methanol, and Optima grade LC/MS water was purchased from ThermoFisher 
Scientific (Waltham, MA, USA). 
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2.3.2 Size reduction by high-pressure homogenization 
For preparation of multistep purified formulations, 1% (w/v) CAB was added to a 
solution of 0.3% (w/v) P407 and 0.2% (w/v) FA-P407 in endotoxin free water (Figure 2.1). 
For optimized direct preparation, 5% to 20% (w/v) CAB was premixed with 0.15% to 0.60% 
(w/v) FA-P407 solution (CAB to FA-P407 ratio was 100:3). Polymer stabilized drug 
suspensions were stirred with magnetic stir bar for at least 16 hours at room temperature 
	
Figure 2.1 Size reduction scheme for FA NCAB prepared with purification procedure. 1% 
(w/v) CAB was dispersed in polymer solution containing both targeted and non-targeted P407 
polymer, followed by high-pressure homogenization until the desired particle size and PdI are 
achieved. The size-reduced particles contain excessive polymers that need further purification. 
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followed by homogenization with high-pressure homogenizer (Avestin EmulsiFlex-C3; 
Avestin Inc., Ottawa, ON, Canada) at 20,000 psi until reaching a desired particle size of ~ 
300 nm.  
2.3.3 Formulation purification by differential centrifugation 
Crude nanosuspensions were purified by a serial of centrifugations [8]. The 
homogenized suspension was first centrifuged at 10,000 × g for 15 min. The supernatant 
was discarded and the pellet was re-suspended in 0.2% (w/v) P407 solution. The re-
dispersed nanoparticles were centrifuged at 200 × g for 1 min to remove large particles that 
were poorly dispersed. Supernatant from the secondary centrifugation was collected as the 
final formulation. 
2.3.4 Formulation purification by tangential flow filtration (TFF)  
Homogenized suspensions were diafiltrated by Kros Flo research IIi TFF system 
(Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA) with mPES MidiKros® 
Filter Module (cut-off size: 0.2 µm; surface area: 20 cm2) to remove unbounded polymer. 
For a 15 mL suspension, the formulation was concentrated to 5 mL followed by 
diafiltration with 5 or 10 diavolume (DV) of water. 
2.3.5 Physicochemical characterizations 
Effective diameter (Deff), polydispersity index (PdI), and ζ-potential of the 
nanoformulations were assessed by dynamic light scattering (DLS) using a Malvern 
Zetasizer, Nano Series Nano-ZS (Malvern Instruments, Inc., MA, USA). Encapsulation 
efficiency of the formulations was calculated using following equation: 
Encapsulation	efficiency	 % = 234567	89	:;<5	4=	98;><?@748=
234567	89	:;<5	93:	4=474@??A
×100. The morphology of the 
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nanoformulations was examined by scanning electron microscopy (SEM) using a Hitachi 
S4700 field-emission scanning electron microscope (Hitachi High Technologies America, 
Inc., IL, USA). Proton nuclear magnetic resonance (1H-NMR) was used to test drug to 
polymer ratio in the FA NCAB formulation. 
2.3.6 FA content detection  
Absorbance at 380 nm was tested for FA concentrations within FA NCAB formulations 
prepared by centrifugation purification, TFF purification (5 and 10 DV), and direct method. 
1 mL of DMSO was added to ~ 100 mg of formulation lyophilized powder followed by 
sonication and shake overnight to extract FA-P407. Drug particles that were not dissolved 
in DMSO were removed by centrifugation at 10,000 × g for 10 min. DMSO supernatant 
was collected to measure FA characteristic absorbance at 380 nm by SpectraMax M3 
Multi-Mode Microplate Reader (Molecular Devices, LLC., Sunnyvale CA, USA). FA 
content was quantitated by comparison of absorbance to those of known standards (0-1000 
µg/mL in DMSO). 
2.3.7 FA NCAB monocyte-derived macrophages (MDM) uptake 
Human peripheral blood monocytes were obtained and cultured as described.[11] 
Briefly, peripheral blood monocytes were obtained by leukapheresis from HIV-1/2 and 
hepatitis B seronegative donors, followed by purification by countercurrent centrifugal 
elutriation. Monocytes were cultured in DMEM supplemented with 10% heat-inactivated 
pooled human serum, 10 µg/mL ciprofloxacin, 50 µg/mL gentamicin, and 1,000 U/mL 
recombinant macrophage colony stimulating factor during monocyte-macrophage 
differentiation. Cells were treated with 100 µM CAB nanoformulations. At predetermined 
time points, MDM were washed three times with sterile phosphate-buffered saline (PBS) 
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and scraped into 1 mL PBS. Cell pellets were collected by centrifugation at 1,000 × g for 
8 min, followed by probe sonication in 200 µL HPLC grade methanol to extract CAB. Drug 
content was quantitated by comparison of peak area to those of known standards (0.05–50 
µg/mL in methanol). 
2.3.8 CAB concentration detection  
MDM uptake samples were tested for CAB concentration by Waters ACQUITY ultra 
performance liquid chromatography (UPLC) H-Class System with TUV detector and 
Empower 3 software (Milford, MA, USA). CAB samples were separated on a Phenomenex 
Kinetex 5 µm C18 column (150 × 4.6 mm) (Torrance, CA) using either 65% 5.0 mM 
KH2PO4, pH 3.2/35% ACN with a flow rate of 1.0 mL/min and detected at 254 nm. Drug 
content was quantitated by comparison of peak area to those of known standards (0.05–50 
µg/mL in methanol). 
2.3.9 PK determinations 
PK profiles of FA NCAB prepared by direct method or TFF purification were evaluated 
in male BALB/cJ mice (Jackson Labs, Bar Harbor, ME, USA). CAB LAP was used as 
non-targeted control formulation. Mice were dosed with each formulation at 45 mg/kg and 
followed by blood collection after cheek bleeding at days 3, 7, 14, 21 and 28. Plasma was 
collected from heparinized tubes after centrifugation at 2,000 × g for 5 min. At day 28 after 
administration, mice were sacrificed and liver, spleen, and lymph node tissues were 
collected after PBS perfusion. Plasma and tissue CAB concentrations were measured by 
ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) as 
previously described [12]. Non-compartmental PK analysis for plasma CAB was 
performed using WinNonlin-5.1 (Certara USA, Inc., Princeton, NJ, USA). 
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2.3.10 Ethics 
Human monocyte collections were deemed exempt by the University of Nebraska 
Medical Center (UNMC) Institutional Review Board. The animal study was conducted 
under a protocol approved by the UNMC Institutional Animal Care and Use Committee in 
accordance with the standards incorporated in the Guide for the Care and Use of Laboratory 
Animals (National Research Council of the National Academies, 2011).  
2.4 Results 
2.4.1 FA NCAB purification by differential centrifugation 
 A general scheme designed to reduce the drug crystalline size is illustrated in Figure 
2.1. FA NCAB is produced by premixing CAB (1% w/v) with P407 (0.3% w/v) and FA-
P407 (0.2% w/v) solution using a magnetic stir bar. This process breaks any chunk 
materials that may block the homogenizer in the following process. High-pressure 
homogenization further reduced Deff to 312 nm with PdI of 0.228 and negative surface 
charge (Table 2.1 before purification).  
Table 2.1 FA NCAB physicochemical properties 
Method Purification Deff (nm) PdI ζ-potential (mV) 
Differential 
centrifugation 
- 312 ± 3 0.228 ± 0.013 -30.5 ± 1.2 
+ 454 ± 5 0.180 ± 0.029 -22.1 ± 0.4 
Tangential flow 
filtration 
- 290 ± 2 0.263 ± 0.013 -29.0 ± 0.4 
+ (5 DV) 285 ± 4 0.258 ± 0.019 -28.6 ± 0.8 
+ (10 DV) 295 ± 2 0.267 ± 0.016 -22.5 ± 0.3 
Direct preparation - 319 ± 5 0.277 ± 0.041 -37.8 ± 1.9 
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To remove unbound FA-P407 that may compete for receptor binding, differential 
centrifugation was used. The process involves high-speed centrifugation and re-dispersion 
of the pellet in a P407 solution (Figure 2.2).  
Approximately thirty percent of the drug was lost during this process. Encapsulation 
efficiency was 72%. After centrifugation procedures, particle size increased from 312 nm 
to 454 nm with reduced surface charge (Table 2.1). The size increase is due to the 
formation of aggregates that are readily observed by SEM (Figure 2.3 A). According to 
UV/Vis measurement, there was 3.2 ± 0.6 µmol FA per gram of lyophilized formulation 
powder. Despite increased particle size, FA NCAB maintained its targeting ability. As 
shown in Figure 2.3 B, FA NCAB treatment resulted in approximately two times greater 
drug concentration in MDM compared to parallel NCAB formulation without FA-P407. 
	
Figure 2.2	 Post homogenization process scheme of FA NCAB purified by differential 
centrifugation. High speed centrifugation at 10,000 × g was used to pellet FA NCAB followed 
by resuspension in 0.2% (w/v) P407 solution. Large particles that cannot disperse during 
resuspension were removed by low speed centrifugation at 200 × g. 
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The highest drug concentration was observed at 4 hours after treatment for FA NCAB (12.5 
µg/106 MDM) and NCAB (7.8 µg/106 MDM) after which drug concentration decreased.  
 
2.4.2 FA NCAB preparation by TFF 
To preclude particle aggregation caused by harsh pressure during high-speed 
centrifugation, TFF was tested to remove unbound FA-P407 (Figure 2.4).  
	
Figure 2.3 Evaluation of FA NCAB prepared by differential centrifugation. (A) Morphology 
of FA NCAB purified by centrifugation was visualized by SEM. Scale bar: 5 µm. (B) Cellular 
uptake of FA NCAB prepared by differential centrifugation was assessed in human MDM and 
compared to nanoformulation without targeting ligand (NCAB). Intracellular drug 
concentrations were determined in MDM receiving 100 µM NCAB or FA NCAB treatment for 
1-8 hours. Intracellular drug concentrations were analyzed by HPLC-UV/Vis. Data are 
expressed as mean ± SD for n = 3 samples per group. For each time point, means were compared 
by two-tailed Student's t-test. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Both 5 and 10 DV of water were used for the diafiltration. TFF successfully maintained 
the Deff and PdI of FA NCAB nanoparticles (Table 2.1). The encapsulation efficiency was 
78.2% (5 DV) and 70.4% (10 DV), respectively. Notably, after TFF purification without 
an additional stabilizer, both 5 and 10 DV water washed formulations were stable in Deff, 
PdI, and ζ-potential for at least one month (Figure 2.5 A). The morphology of the TFF 
purified FA NCAB was more homogeneous compared to formulation prepared by 
differential centrifugation (Figure 2.5 B). FA content was 4.1 ± 0.5 and 9.7 ± 0.4 µmol/g 
lyophilized formulation respectively for 5 and 10 DV water washed FA NCAB 
formulations. MDM uptake study (Figure 2.5 C) indicated a maintained FA targeting 
ability after TFF purification. Cellular CAB concentrations were 2-3 fold greater for TFF 
purified FA NCAB compared to non-targeted NCAB formulation. 
	
Figure 2.4 Manufacturing scheme for FA NCAB purified by TFF. FA NCAB was purified by 




Figure 2.5	Evaluation of FA NCAB prepared by TFF. (A) Time course measurements of FA 
NCAB prepared by TFF for Deff, ζ-potential, and PdI. Data are expressed as mean ± SD for n = 
3 measurements. (B) Morphology of FA NCAB purified by TFF was visualized by SEM. Scale 
bar: 5 µm. (C) Cellular uptake of FA NCAB prepared by TFF was assessed in human MDM 
and compared to formulation without targeting ligand or NCAB. Intracellular drug 
concentrations were determined in MDM treated with 100 µM NCAB or FA NCAB for 2 and 
4 hours. Intracellular drug concentrations were analyzed by HPLC-UV/Vis. Data are expressed 
as mean ± SD for n = 3 samples per group. one-way ANOVA followed by Tukey's post hoc test 
was used to compare FA NCAB with non-targeted NCAB formulation. ***P < 0.001. 
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2.4.3 Direct manufacture 
	Having successfully produced stabilizer-free TFF-purified FA NCAB nanoparticles, 
we determined the polymer content of the nanoparticles to facilitate development of a 
simplified direct manufacturing scheme for ligand-targeted nanoformulations to bypass the 
need for purification. TFF-purified FA NCAB was lyophilized and drug to polymer ratios 
were determined by evaluation of integral areas in the 1H-NMR spectrum. As shown in 
Figure 2.6, the characteristic peak (a) with a chemical shift at 5.36 ppm corresponds to a 
single proton from CAB, while peak (b) corresponds to 930 protons from polyethylene 
glycol and polypropylene glycol repeating units of P407.  
	
Figure 2.6 1H-NMR of lyophilized FA NCAB formulation purified by TFF. Drug to P407 
ratio was calculated based on integration of the characteristic peaks of CAB and P407. 
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The CAB to P407 ratio (w/w) for TFF purified formulations was calculated based on 
integral values of the assigned protons in the spectrum. To optimize manufacture 
conditions, variant drug to polymer ratios were tested within the range of 16:1 to 45:1. FA 
NCAB prepared directly are protected against mechanical stresses such as centrifugation 
or TFF that could damage the particle. Direct manufacturing also permits high drug loading 
without compromising particle integrity. High-pressure homogenization then achieved a 
stable particle size and narrow PdI for nanocrystals containing up to 20% (w/v) CAB (data 
not shown). The optimized formulation procedure is illustrated in Figure 2.7. Pure FA-
P407 was used with a drug to polymer ratio of 100:3 with FA-P407 only. This precludes 
any polymer exchanges between targeted and non-targeted polymers that could affect 
targeting ability of the formulation. Directly prepared FA NCAB was stable by Deff, PdI, 
and ζ-potential for up to 80 days. Thereafter, nanoparticles began to increase in size 
(Figure 2.8 A). Direct prepared FA NCAB was homogeneous in morphology as tested by 
SEM (Figure 2.8 B). The elimination of post homogenization purification steps resulted 
	
Figure 2.7 Manufacturing scheme of FA NCAB prepared by a direct method. 
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in a   99% encapsulation efficiency. FA content was 9.0 ± 1.3 µmol/g lyophilized 
formulation, which is similar to the formulation purified by TFF with 5DV of water.  The 
	
Figure 2.8	 Evaluation of FA NCAB manufactured by direct method. (A) Time course 
measurements of direct prepared FA NCAB over 120 days for Deff, ζ-potential, and PdI. Data 
are expressed as mean ± SD for n = 3 measurements. (B) Morphology of FA NCAB prepared 
by the direct method was visualized by SEM. Scale bar: 5 µm. (C) MDM uptake of NCAB and 
FA NCAB prepared by the direct method. MDM were treated with 100 µM NCAB or FA 
NCAB, and intracellular drug concentrations were analyzed by HPLC-UV/Vis at 1, 2, and 4 
hours after drug treatment. Data are expressed as mean ± SD for n = 3 samples. For each time 
point, means were compared by two-tailed Student's t-test. **P < 0.01, ***P < 0.001. (D) 
Competitive uptake study of FA NCAB. Cells were pretreated with free FA (0-25 mM) for 30 
min to block folate receptors, followed by FA NCAB treatment. Data are expressed as mean ± 
SD for n = 3 samples. 
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targeting ability of FA was confirmed by MDM uptake study that FA NCAB treatment 
resulted 7.8 µg/106 MDM intracellular drug concentration at 4 hours, which is approximate 
four times of the NCAB treated cells (2.0 µg/106 MDM) (Figure 2.8 C). In the presence 
of free FA, FA NCAB uptake by MDM was reduced to a level that is close to non-targeted 
NCAB treated cells. Four-hour cellular drug concentration was 2.6 µg/106 cells after co-
incubated with 25 mM free FA for 4 hours (Figure 2.8 D). 
2.4.4 PK evaluation 
Male BALB/cJ mice were injected intramuscularly 45 mg/kg FA NCAB prepared by 
TFF or the direct method to assess PK (Figure 2.9) and BD (Figure 2.10) in comparison 
to non-targeted CAB 
LAP. Fourteen days 
after injection, animals 
treated with FA NCAB 
prepared by both 
methods showed greater 
plasma drug 
concentrations (22,050 
ng/mL for TFF purified 
and 22,780 ng/mL for 
direct prepared, 
respectively) compared 
to CAB LAP treated 
mice (15,250 ng/mL). 
	
Figure 2.9 FA NCAB PK profiles in male BALB/cJ mice. Mice 
were administered intramuscularly 45 mg/kg FA NCAB purified 
by TFF or direct prepared to 45 mg/kg CAB LAP treatment. 
Plasma was collected at days 3, 7, 14, 21 and 28 after drug 
administration and CAB concentrations were determined by 
UPLC/MS/MS. Data represent mean ± SEM for n = 5 mice per 
group. 
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FA NCAB manufactured by the direct method provided sustained high plasma drug levels 
to day 28 (14,400 ng/mL), whereas TFF prepared FA NCAB exhibited a faster decay rate 
and at 28 days the plasma drug concentration (3,679 ng/mL) was close to that in CAB LAP 
treated animals (3,125 ng/mL) (Figure 2.9). Non-compartmental PK analysis was 
performed for all the formulations (Table 2.2).  
 
Table 2.2 Non-compartmental PK analysis 
 
Direct prepared FA NCAB resulted in 3-fold longer apparent terminal phase half-life 
(t1/2) compared to CAB LAP (22.3 compared to 6.9 days), while TFF prepared FA NCAB 
did not exhibit significant improvement (t1/2 was 7.7 days). Similarly, volume of 
distribution (Vβ/F) was increased while clearance (CL/F) was reduced in direct prepared 
FA NCAB treated mice. Tissue drug levels in liver, spleen and lymph nodes at day 28 
correlated with the plasma drug concentrations. Direct prepared FA NCAB provided 
greater tissue drug concentrations in liver, spleen, and lymph nodes compared to FA NCAB 
prepared by TFF and CAB LAP (Figure 2.10).  
PK Parameters CAB LAP FA NCAB (Direct) 
FA NCAB 
(TFF) 
λZ (1/day) 0.100 0.031 0.090 
t1/2 (day) 6.9 22.3 7.7 
AUClast (day*ng/mL) 546640.6 726640.0 650934.0 
AUC0-∞ (day*ng/mL) 577934.2 1189658.7 691786.8 
AUC % 
Extrapolation 5.41 38.92 5.91 
Vβ/F (L/kg) 0.78 1.22 0.72 
CL/F (L/day/kg) 0.08 0.04 0.07 




To adjust tonicity and to further stabilize FA NCAB formulation prepared by the direct 
method, we examined a variety of buffers, stabilizers, and tonicity adjusters (Table 2.3). 
Salts including phosphate buffer, PBS, HEPES, histidine, and sodium carboxymethyl 
cellulose reduced FA NCAB stability resulting in greater than 50% increase in Deff to over 
500 nm. For example, 0.2% (w/v) sodium carboxymethyl cellulose in FA NCAB resulted 
a size increase from 300 nm to 1,042 nm with a broad size distribution (PdI > 0.5). Histidine 
increased particle size gradually. At 7 days following particle preparation, Deff was 688 nm 
with a PdI of 0.296. Sugars including sucrose, dextrose, trehalose, glucose, and mannitol 
elicited a stable particle size and PdI for one month or longer. PEG 3350 is an excipient in 
the CAB LAP formulation [3]. Thus, we tested PEGs with different molecular weights. 
PEG 2000 and 3350 were compatible with FA NCAB while the higher molecular weight 
PEG 4600 resulted in increases in Deff to > 500 nm one week after preparation.  
	
Figure 2.10 FA NCAB tissue distribution in BALB/cJ mice.	Tissues were collected at day 28 
and CAB concentrations were determined by UPLC/MS/MS.  Data are expressed as mean ± 
SEM for n = 5 mice per group. Tissue CAB concentrations were compared by one-way ANOVA 
followed by Tukey's post hoc test. *P < 0.05, **P < 0.01. 
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Table 2.3 The effect of additives on FA NCAB stability 
Excipients Concentration pH 
Formulation 
stability (weeks)* 
Phosphate buffer - 6.8 0 
Phosphate buffered saline - 6.8 0 
HEPES buffer 10 mM 6.8 0 
Histidine 0.2% (w/v) 6.8 1 
Sodium carboxymethyl 
cellulose 
0.2% (w/v) NA 0 
Sucrose 0.2%; 1%; 2% (w/v) NA >4 
Dextrose 0.2%; 1%; 2% (w/v) NA >4 
Trehalose 0.2%; 1%; 2% (w/v) NA >4 
Glucose 0.5% (w/v) NA 9 
Mannitol 0.5% (w/v) NA 8 
PEG 2000 0.5% (w/v) NA >3 
PEG 3350 0.5% (w/v) NA >3 
PEG 4600 0.5% (w/v) NA 1 
P407 0.5% (w/v) NA >3 
P188 0.5% (w/v) NA >3 
*The formulations were considered to be unstable when Deff > 500 nm and/or PdI > 0.3 
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 Additional P407 and P188 did not affect the stability of FA NCAB. Mannitol and glucose 
were selected for further stability evaluation under variable temperature conditions. As 
shown in Figure 2.11, without additives FA NCAB was stable for at least 63 days at 4, 25, 
and 37 °C. 63 days after adding 0.5% (w/v) glucose, Deff increased from 350 nm to 378 nm 
(4 °C), 381 nm (25 °C), and 483 nm (37 °C), respectively. 37 °C storage also resulted in a 
	
Figure 2.11	 Formulation additives and FA NCAB stability. (A) Time course stability 
measurements of direct prepared FA NCAB for Deff, ζ-potential, and PdI when stored at 4, 25, 
and 37 °C, respectively. Direct prepared FA NCAB was then mixed with (B) glucose or (C) 
mannitol with final concentration of 0.5% (w/v). Deff, ζ-potential, and PdI for FA NCAB with 
additives were monitored for over 60 days at 4, 25, and 37 °C. Data are expressed as mean ± 
SD for n = 3 measurements. 
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PdI more than 0.3 after day 49. Additional mannitol was able to maintain stable Deff and 
narrow PdI until 35 and 56 days when stored at 4 and 25 °C respectively. At 37 °C, there 
was a slight increase of the Deff at day 3 to approximately 390 nm, which was maintained 
afterwards. This result indicated that glucose is better additive compared to mannitol for 
maintaining FA NCAB integrity. FA NCAB with 0.5% (w/v) glucose can be stored at room 
temperature. Macrophage uptake measurements (Figure 2.12) demonstrated that 
additional mannitol or 
glucose did not 
negatively affect 
particle cell entry. On 
the contrary, both 
glucose and mannitol 
accelerated MDM 
uptake. Highest cellular 
drug concentrations 
were observed at two 
hours after treatment 
compared to four hours 
for the plain FA NCAB 
treated cells.  
2.5 Discussion 
LA medicines show promises in achieving improved therapeutic outcomes for 
HIV/AIDS. Prolonged dosing intervals and less fluctuation in plasma drug concentrations 
	
Figure 2.12	FA NCAB uptake in MDM with or without glucose 
and mannitol. MDM were treated with 100 µM FA NCAB with or 
without 0.5% (w/v) glucose (G) and mannitol (M) addition. 
Intracellular drug concentrations were determined at 1, 2 and 4 
hours after treatment. Data are expressed as mean ± SD for n = 3 
samples per group. 
	 48 
can result in improved regimen adherence, reductions in systemic toxicities, reduced viral 
mutations, and reduced HIV stigmas related to daily observed ART usage [1, 13]. 
Nevertheless, as described in chapter I, a successful regimen requires high drug 
encapsulation and loading that would maintain sufficient amount of API for months within 
readily injectable volume. In addition, loaded drugs have to be released in a pattern that is 
sufficient to provide therapeutic drug concentration, yet slow enough to avoid any high 
blood drug concentration induced toxicities and to achieve prolonged dosing intervals.  
Nanocrystals is an ideal strategy to formulate hydrophobic API for LA purpose. They 
can provide high drug loading capacity while obviating organic solvent usage therefore 
reduce relevant toxicities [14]. After injection of the nanocrystals, the injection site serves 
as a primary depot from where drug is dissolved and eventually released into the blood 
stream. Sustainable release for weeks/months can be achieved with API that has low 
aqueous solubility. RPV and CAB LA formulations are both nanocrystals with 
approximately 200 nm of size manufactured by wet-milling. It is a commonly used top-to-
bottom method to break down particle size for hydrophobic drug crystalline API. Including 
surfactants such as polysorbate 20 (CAB) and poloxamer 338 (RPV) is essential to prevent 
particle agglomeration [3, 4]. For FA NCAB, nanocrystals were made by high-pressure 
homogenization in the presence of P407, which serves as the surfactant stabilizer. High-
pressure homogenization is another size reduction technique that breaks down particle size 
via forcing of a suspension under pressure through a valve with a narrow aperture [14, 15]. 
This method presumably precludes contamination from worn beads that are used for wet-
milling. 
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Macrophages and CD4+ T cells are primary target cells and reservoirs for HIV-1 [16-
18]. Our laboratory has been working on the development of LASER ART to target 
infected and reservoir cell populations [8, 12, 19, 20]. Herein, macrophages are used as 
“Trojan horses” serving as additional depot. Specifically, macrophages are highly mobile 
cells and readily cross physiological barriers to sites of inflammation and infection. Drug 
crystals in the endosomal compartments of macrophages can therefore across physiological 
barriers to viral reservoirs such as the gut, brain and lymph node [21, 22]. Depending on 
surface chemistry and lipophilic properties, nanoparticles phagocytosed by macrophages 
can be disseminated from vesicles in the cytoplasm into the surrounding tissues and blood 
stream. This secondary depot effect results in reduced maximal plasma drug concentration 
(Cmax) and prolonged apparent half-life (t1/2) in drug PK profiles, which could potentially 
reduce overall dosage as well as drug Cmax-induced toxicities [14].  
One strategy to enhance macrophage uptake is by incorporating macrophage specific 
targeting ligands on the surface of the nanocrystals. One well evaluated targeting ligand 
for macrophage is FA. Indeed, we demonstrated that FA decorated ART nanocrystals can 
enhance macrophage ART uptake and retention and improve PK and antiretroviral profiles 
[8, 9, 23]. Nevertheless, one obstacle for translational application of such ligand-targeted 
formulations is the complexity in manufacturing process. Purification steps such as 
differential centrifugation, dialysis, and filtration are considered to be essential to remove 
any unbound targeted moieties that may compete for receptor binding. However, these 
purification steps are often time consuming and, in worst scenario, they may jeopardize the 
integrity nanoparticles causing particle aggregation and loss of targeting ability. Herein, 
we evaluated differential centrifugation and TFF purification methods. Based on the 
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stability profiles of purified formulations, we were able to synthesize FA NCAB directly 
without any purification process by optimizing drug to polymer ratios.  
In this study, MDM were used to evaluate the targeting ability of FA NCAB at cellular 
level. Despite the manufacturing process, increased cellular drug levels were observed for 
FA NCAB formulations compared to parallel non-targeted NCAB formulations. 
Formulation prepared by differential centrifugation exhibited highest drug concentrations 
(Figure 2.3 B) as compared to TFF purified (Figure 2.5 C) and directly prepared (Figure 
2.8 C) formulations. This is due to the macrophage’s preference of taking larger particle 
size objects [24]. However, formulations prepared by differential centrifugation are not 
easily translational because the lack of homogeneity and non-reproducible resuspension 
process. TFF purification provided homogenous and reproducible particle size. 
Additionally, FA targeting ability was confirmed by MDM uptake study (Figure 2.5 C). 
However, it only transformed into transit increase in plasma drug concentration in PK study 
(Figure 2.9), which could be because of the polymer exchanges between targeted and non-
targeted P407 on the surface of the particles. Indeed, optimized FA NCAB with only FA-
P407 exhibited prolonged improvement in plasma drug level. The direct manufacturing 
scheme also minimizes drug loss during purification steps and provided the highest 
encapsulation efficiency. 
Because only a limited amount of polymer was used, tonicity adjusters will be required 
for injection and additional stabilizers might be necessary for long-term storage as well. 
Salts were incompatible with FA NCAB formulation most likely due to electrostatic 
interactions with CAB molecule that could disrupt the surface of nanoparticles. Sugars 
such as glucose and mannitol, in contrast, maintained FA NCAB stability under long-term 
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storage conditions. Notably, FA NCAB can be stored at room temperature for prolonged 
period of time. 
2.6 Conclusions 
Taken together, while current LA ART nanoformulations demonstrate real potential 
for improved HIV management and prevention, further refinements in medicinal and 
polymer chemistry, as recently demonstrated, could produce optimal intracellular and 
tissue drug delivery and would further improve viral restriction [12, 25]. Targeting ligand 
decoration is an important aspect of LASEAR ART development. Current study focused 
on addressing the technique hurdles that are commonly known for ligand-targeted 
formulation preparation. The resultant manufacturing procedure is highly reproducible and 
scalable and could be applied to analogous formulation platforms, which is certainly a step 
forward in development of the next generation of LA ART for human use.  
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LA ART have opened a new chapter for treatment and prevention of HIV-1 infection. 
As mentioned in Chapter I, CAB is the one of the first LA ART. It is a highly potent INSTI, 
with a half-life of up to 54 days, allowing for every other month parenteral administrations. 
Despite these promising profiles, our previous study indicated a short a short cellular 
retention of CAB. High volume dosing, injection site reactions and low body fluid drug 
concentrations are the limitations that hinder the broad applications for HIV infected and 
susceptible people. To address above issues, especially the short cellular retention, we 
synthesized a myristoylated CAB prodrug (MCAB). MCAB exhibited increased 
lipophilicity and hydrophobicity, and unchanged antiretroviral activity as compared to 
native CAB. MCAB was then formulated into nanocrystals (NMCAB), which is stable in 
size with a shape that facilitates avid monocyte-macrophage entry, retention. Sustained 
protection against HIV-1 challenge was achieved in MDM as compared to CAB LAP and 
parallel NCAB formulation without chemical modification. We conclude that 
myristoylation of CAB followed by nanoformulation can facilitate MDM uptake and 
retention, which could translate into improved and prolonged antiretroviral activity against 
HIV infection. 
3.2 Introduction  
LA ART is an important milestone in HIV/AIDS field recent years to improve patient 
adherence [1]. Changes in treatment patterns from daily oral to monthly or even less-
frequent administration may also provide greater patient privacy and satisfaction [2, 3]. A 
survey conducted in 400 HIV-1 seropositive patients indicated that 73% of patients would 
consider switching from daily pill regimens to LA regimens [4]. Despite current promises 
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in LA CAB and RPV development, improved therapeutic outcomes can be achieved by 
further prolong dosing interval and enhance ART delivery into viral reservoirs. In chapter 
II, we discussed means to improve LA ART delivery by macrophage-targeted delivery with 
FA decorated nanoparticles to target highly expressed folate receptor 2 on the surface of 
activated macrophages. FA NCAB enhanced MDM uptake and prolonged t1/2 for 3-times. 
Yet, cellular retention was limited as observed in MDM uptake study that cellular drug 
level declined eight hours after treatment (Figure 2.3 B), which is presumably due to the 
intrinsic properties of CAB compound as the decline of cellular drug concentrations were 
observed for both targeted and non-targeted CAB formulations.  
Progress in medicinal chemistry and nanotechnology has provided new opportunities 
to improve ART delivery. Diverse strategies including chemical modification are being 
tested to improve ART delivery [5-7]. Modifications in antiretroviral drug structures and 
delivery platforms can facilitate drug depot formation and lymphoid targeting [8-10], and 
have the potential to better penetrate HIV reservoirs, lower drug dosing, and reduce 
systemic toxicities [10-12]. Hereby in this chapter, prodrug strategy was tested to address 
the limitation of short cellular retention as observed for CAB formulations. To these ends, 
we designed a CAB nanoformulated prodrug, aiming to improve the drug’s lipophilicity, 
hydrophobicity, and cellular entry and retention to facilitate the drug’s ability to access 
anatomical reservoirs while maintaining high plasma concentrations. The result was a 
nanoformulated myristoylated CAB (NMCAB) with tailored formulation modifications 
that enhance MDM uptake and antiretroviral activities. 
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3.3 Materials and Methods 
3.3.1 Materials 
Native CAB and CAB LAP (200 mg/mL) were kind gift from ViiV Healthcare 
(Research Triangle Park, NC, USA). Myristoyl chloride, P407, N,N-diisopropylethylamine 
(DIEA), dimethylformamide (DMF), 1-octanal, ciprofloxacin, were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). DMEM was purchased from Corning Life Sciences 
(Tewksbury, MA, USA). Heat-inactivated pooled human serum was purchased from 
Innovative Biologics (Herndon, VA, USA). Cell counting kit-8 (CCK-8) was purchased 
from Dojindo Molecular Technologies, Inc. (Rockville, MD, USA). Gentamicin, and 
HPLC grade ACN, HPLC grade methanol from ThermoFisher Scientific (Waltham, MA, 
USA). Monoclonal mouse anti-human HIV-1p24 (clone Kal-1), monoclonal mouse anti-
human leukocyte antigen (HLA-DR; clone CR3/43), and the polymer-based HRP-
conjugated anti-mouse EnVision+ secondary were all purchased from Dako (Carpinteria, 
CA, USA). 
3.3.2 Myristoyl CAB (MCAB) synthesis  
Synthesis of MCAB was conducted according to the route illustrated in Figure 3.1. 
Briefly, CAB (4.9 mM, 1 equivalent) was dispersed in approximately 35 mL of anhydrous 
DMF and cooled on ice before deprotonation with DIEA (9.8 mM, 2 equivalents). 
Myristoyl chloride (9.8 mM, 2 equivalents) was then added and the reaction mixture was 
stirred at room temperature for 16 hours. After confirmation of reaction completion by 
thin-layer chromatography (TLC), the mixture was concentrated and the product was 
isolated by flash silica gel chromatography using a mixture of ethyl acetate and hexane 
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(4:1). The fractions containing UV active MCAB were dried and washed with diethyl ether, 
followed by drying under vacuum to obtain the final product. 
 
3.3.3 Physicochemical characterizations of MCAB 
1H-NMR spectra of CAB and MCAB were recorded on a Varian Unity/Inova-500 NB 
(500 MHz; Varian Medical Systems Inc., Palo Alto, CA, USA). 1H-NMR data is reported 
in parts per million (ppm) downfield from tetramethylsilane as an internal standard. Fourier 
transform infrared spectroscopy (FT-IR) analysis was performed using a Spectrum Two 
FT-IR spectrometer (PerkinElmer, Waltham, MA, USA). Comparative crystallographic 
analyses of CAB and MCAB by powder X-ray diffraction (XRD) were carried out in the 
2θ range of 2–50° using PANalytical Empyrean diffractometer (PANalytical Inc., 
Westborough, MA, USA) with Cu-Kα radiation (1.5418 Å) at 40 kV, 45 mA setting. A 
mask of 20 mm and a divergence slit of 1/8° were used on the incident beam path. A nickel 
foil filter was used to eliminate the diffraction peaks due to possible Kb wavelength.  
	
Figure 3.1 MCAB synthetic route 
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3.3.4 Solubility test 
The solubility of CAB and MCAB in water and 1-octanol was determined by adding 
excess drug to each solution at room temperature then mixing for 24 hours. Samples were 
centrifuged at 20,000 × g for 10 min to pellet insoluble drug. The supernatants containing 
solubilized drug were freeze-dried then re-dispersed in methanol for drug concentration 
measurement by Waters ACQUITY ultra performance liquid chromatography (UPLC) H-
Class System with TUV detector and Empower 3 software (Milford, MA, USA). CAB 
detection method was described in Chapter II, 2.3.8. MCAB samples were also separated 
on a Phenomenex Kinetex 5 µm C18 column (150 × 4.6 mm) (Torrance, CA, USA). The 
mobile phase was 90% ACN/10% water with a flow rate of 1.0 mL/min. MCAB was 
determined at 230 nm absorbance. Drug content was quantitated by comparison of peak 
area to those of known standards (0.05–50 µg/mL in methanol). 
3.3.5 Half maximal inhibitory concentration (IC50) evaluation 
CAB and MCAB IC50 against HIV-1ADA was tested in MDM. Human monocytes were 
obtained and differentiated into macrophages as described in Chapter II, 2.3.7.  MDM were 
then treated with various concentrations (0.06-1000 nM) of native CAB or MCAB for 30 
min, followed by HIV-1ADA challenge at a multiplicity of infection (MOI) of 0.1 infectious 
viral particles/cell. Four hours after challenge, cells were washed three times with sterile 
PBS and then incubated with the same concentration of each compound used before 
infection. Cells were cultured for additional seven days with half-media changes every 
other day with DMEM media that contains the same drug concentrations. Supernatants 
were collected seven days after the challenge for HIV reverse transcriptase (RT) activity 
determination as previously described [13, 14]. Data were then transformed into percentage 
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of reduced RT activity as compared to HIV positive control RT activity. Nonlinear 
regression was performed using log (drug concentration) vs. inhibition rate with variable 
slop for IC50 calculation.  
3.3.6 Nanoformulation preparation 
NMCAB and nanoformulated CAB (NCAB) were manufactured by high-pressure 
homogenization (Avestin EmulsiFlex-C3; Avestin Inc., Ottawa, ON, Canada). Briefly, 
MCAB or CAB (5% w/v) was premixed in a P407 solution (0.5% w/v in endotoxin free 
water) for at least 16 hours at room temperature followed by homogenization at 20,000 psi 
until the desired particle size of approximately 300 nm was achieved [34].  
3.3.7 Nanoformulation characterization 
Deff, PdI, and ζ-potential were assessed by DLS as described in Chapter II, 2.3.5. 
Particle morphology was determined using a Hitachi S4700 field emission SEM (Hitachi 
High Technologies America Inc, Schaumburg, IL, USA). The crystalline structures of 
lyophilized CAB LAP and NMCAB were determined by XRD and compared against CAB 
or MCAB as described above. Drug loadings and encapsulation efficiencies were 
calculated using the following equations: 
Drug	loading	 % = 234567	89	:;<5	4=	98;><?@748=
234567	89	?A8I64?4J3:	98;><?@748=
×100                                                 (1) 
Encapsulation	efficiency	 % = 234567	89	:;<5	4=	98;><?@748=
234567	89	:;<5	93:	4=474@??A
×100                                   (2) 
The stability of NMCAB was monitored at 4 °C for up to 3 months in terms of Deff, PdI 
and ζ-potential. 
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3.3.8 Cell viability evaluation 
Differentiated MDM in 96-well plates were treated with NMCAB or CAB LAP 
containing 0 – 400 µM drug for 8 hours followed by CCK-8 test according to 
manufacturer’s instruction. Briefly, 10 µL of CCK-8 reagent was added into each well after 
formulation treatment followed by incubation at 37 °C for two hours. Absorbance at 450 
nm was measured using a SpectraMax M3 Multi-Mode Microplate Reader (Molecular 
Devices, LLC., Sunnyvale CA, USA). Wells without cells but containing same 
concentrations of each formulation in culture media were used as blanks. Cell viability was 
calculated using following equation where A represents absorbance at 450 nm of the sample; 
Ab represents absorbance at 450 nm of the blank controls; Ac represents absorbance of 
control cells without any treatment. 
KLMM	NOPQOMORS	 % = 	 TUTV
TWU	TV
×100                                                                                  (3) 
3.3.9 MDM uptake and retention 
To determine nanoformulation uptake, MDM were treated with NMCAB, CAB LAP, 
or NCAB containing 100 µM drug for various durations (2-24 hours). For drug retention 
study, MDM were treated with NMCAB, CAB LAP, or NCAB containing 100 µM drug 
for 8 hours, followed by 3 washes with PBS to remove any extracellular drugs, and culture 
in fresh media for an additional 0-30 days with half medium changes every other day. At 
each time point, uptake and retention cell samples were washed three times with PBS, and 
then scraped into 1 mL of PBS. Cell number for each sample was measured using an 
Invitrogen Countess Automated Cell Counter (Carlsbad, CA, USA). Cell pellets were 
obtained by centrifugation at 1,000 × g for 8 min, and then sonicated briefly in 200 µL 
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methanol followed by centrifugation at 20,000 × g for 10 min at 4° C. The supernatants 
were collected for drug quantitation by UPLC-UV/Vis as described above. 
3.3.10 Transmission electron microscopy (TEM) 
The morphology of macrophages loaded with nanoformulations was imaged by TEM. 
For uptake, MDM were treated with NMCAB or CAB LAP for eight hours. For retention, 
after eight hours drug loading, MDM were washed 3 times with PBS then cultured in fresh 
media for an additional 48 hours. Adherent MDM were washed with PBS for 3 times and 
then scraped into PBS and pelleted by centrifugation at 1,000 × g for 8 min. Cells were 
then fixed by immersion in a solution of 2% glutaraldehyde, 2% paraformaldehyde in 0.1 
M Sorenson’s phosphate buffer (pH 6.2), followed by post-fixation in 1% osmium 
tetroxide for 60 min then dehydration in a graded ethanol series (50, 70, 90, 95, 100%). 
Subsequently, samples were incubated in 50:50 mixture of a propylene oxide:araldite resin 
solution for 16 hours. This was performed to evaporate propylene oxide and was followed 
by additional 2 hours incubation with fresh resin at room temperature prior to embedding 
(65 °C for 24 hours). Sections of 100 nm were prepared with Leica UC6 Ultracut 
ultramicrotome, placed on 200 mesh copper grids, and stained with 2% uranyl acetate, 
followed by Reynolds Lead Citrate. Grids were examined on a Tecnai G2 Spirit TWIN 
(FEI) transmission electron microscope (Hillsboro, OR, USA) operated at 80 kV and 
images were acquired digitally with an AMT digital imaging system (Woburn, MA, USA).  
3.3.11 Statistics 
For all studies, data were presented as mean ± standard deviation (SD), and experiments 
were preformed using a minimum of three biological distinct replicates. For comparison of 
two groups, Student’s t test (two-tailed) was used. For comparison among three groups, 
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one-way ANOVA followed by Tukey’s or Dunnett T3 post hoc test was used based on the 
homogeneity of the samples. No outliers from animal or cell experiments were excluded. 
P < 0.05 was considered to be significant (*P < 0.05; **P < 0.01; ***P < 0.001). All the 
data were analyzed using GraphPad Prism 6.0 software (La Jolla, CA, USA). 
3.4 Results 
3.4.1 Synthesis and structure confirmation of myristoylated CAB (MCAB) 
A fourteen-carbon fatty acid chain modified CAB (MCAB) was synthesized according 
to Figure 3.1. The overall yield of the reaction was 85%. The chemical structure of final 
product was confirmed by 1H-NMR and FT-IR spectra. In MCAB 1H-NMR spectrum 
(Figure 3.2), triplets at 0.88, 1.77 and 2.69 ppm and a broad singlet at 1.26 ppm correspond 
to the terminal methyl and repeating methylene protons of the fatty acid alkyl chain in 
MCAB. Disappearance of the phenol proton peak at 11.5 ppm that is present in CAB 
spectrum confirmed the substitution of CAB’s hydroxyl proton. Additionally, absorption 
bands at 2855 and 2923 cm-1 in MCAB FT-IR spectrum associate with the C-H stretches 
of the fatty acid chain (Figure 3.3). A band at 1760 cm-1 is attributed to the carbonyl C=O 
stretch of the ester bond present in the fatty acid chain.  
3.4.2 MCAB crystal structure, solubility and antiretroviral activity 
Comparative crystallographic analyses of CAB and MCAB by XRD revealed more 
uniform crystals in MCAB where only one major peak was observed (Figure 3.4).	After 
myristoylation, water solubility was reduced from 31.9 ± 14.4 µg/mL (CAB) to 5.6 ± 1.8 
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µg/mL (MCAB), and 1-octanol solubility increased by 30-fold from 44.4 ± 1.3 µg/mL 
	
Figure 3.2	1H-NMR spectra of CAB and MCAB. 
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(CAB) to 1366.5 ± 27.5 µg/mL (MCAB) (Figure 3.5). MCAB and CAB demonstrated 
comparable antiretroviral activities against HIV-1ADA in MDM (Figure 3.6). IC50 was 3.1 
nM (MCAB) and 2.5 nM (CAB) respectively.  
	
Figure 3.3  FT-IR spectra of CAB and MCAB. Circled absorption bands at 1760, 2855 and 
2923 cm-1 are associated with the conjugated fatty acid chain for MCAB. 
	





Figure 3.5 Solubility of CAB and MCAB in water and 1-octanol. The measurement was 
performed at room temperature. Data are expressed as mean ± SD for n = 4 samples per group 
evaluated. The means were compared by two-tailed Student’s t test. * P < 0.05; *** P < 0.001. 
	
Figure 3.6 Antiretroviral activities of CAB and MCAB in HIV-1ADA infected human MDM. 
Inhibition rate was presented as percentage of reduced HIV RT activity as compared to positive 
control RT activity. Nonlinear regression was performed using log (drug concentration) vs. 
inhibition rate with variable slope, and IC50 was calculated. Data are expressed as mean ± SD 
for n = 6 samples per group. 
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3.4.3 Nanoformulated MCAB (NMCAB)  
The manufacture scheme of NMCAB is outlined in Figure 3.7. MCAB was sized-
reduced by high-pressure homogenization with P407 as stabilizer. 
There were two principal controls to evaluate the effectiveness of NMCAB. The first 
was CAB LAP, which is now being tested in clinical trials. The second was CAB 
formulated in the same excipient (P407) used for NMCAB. This formulation is referred to 
as nanoformulated CAB (NCAB), which was manufactured under the same conditions as 
NMCAB but without the chemical modification made to the drug itself. XRD 
crystallographic analyses (Figure 3.8) illustrated unchanged diffractograms for both 
NMCAB and CAB LAP formulations as compared to the unformulated MCAB and CAB 
	
Figure 3.7	NMCAB preparation by high-pressure homogenization 
 
	
Figure 3.8	XRD analysis of lyophilized CAB LAP and NMCAB formulations. 
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(Figure 3.4). This indicated that drug encapsulation with high-pressure homogenization 
did not interfere with drug crystal integrity. Deff, ζ-potential, and PdI of formulations 
determined by DLS are shown in Table 3.1.  
Table 3.1 Physicochemical properties of NMCAB, MCAB, and CAB LAP 
  NMCAB and NCAB were comparable in particle size (318 ± 25 and 315 ± 26 nm 
respectively) with narrow PdI < 0.3 and negative surface charges. CAB LAP exhibited a 
size of 257 ± 6 nm, and similar PdI and ζ-potential with NMCAB. Due to the limited 
amount of excipient usage, high drug loading (90 and 86%) and encapsulation efficiencies 
(91 and 63%) were achieved for NMCAB and NCAB. Rod shape structure, a preferred 
morphology for macrophage uptake [15-17], was observed by SEM for both NMCAB and 
CAB LAP (Figure 3.9). NMCAB was stable with consistent PdI and ζ-potential both in 
water and PBS after storage at 4 °C for up to three months (Figure 3.10).  
Formulation Deff (nm)a PdIa ζ-potential (mV)a 
NMCAB 318 ± 25 0.21 ± 0.02 -22.0 ± 3.4 
NCAB 315 ± 26 0.28 ± 0.04 -8.2 ± 1.4 
CAB LAP 257 ± 6 0.22 ± 0.02 -23.2 ± 1.7 
aEffective diameter (Deff), polydispersity index (PdI) and ζ-potential were determined in water. 
Data are expressed as mean ± SD (n = 3). 
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3.4.4 MDM toxicity evaluation 
CCK-8 assay was applied to investigate the effect of different formulations on MDM 
viability. As shown in Figure 3.11, both NMCAB and CAB LAP treatment had no effect 
on MDM viability with drug concentrations of up to 100 µM. Treatment with formulations 
containing 200 µM drug slightly reduced cell viability to 85.9% (NMCAB) and 86.1% 
(CAB LAP), respectively. There was no statistical difference between the two treatment 
	
Figure 3.9 SEM analysis of morphologies of NMCAB and CAB LAP. Scale bar: 1 µm. 
	
Figure 3.10	NMCAB stability over 90 days. NMCAB was stored at 4 °C for the measurement 
of  Deff, ζ-potential, and PdI in (A) plain water and (B) PBS. Data are expressed as mean ± SD 
for n = 3 measurements. 
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groups. However, 400 µM CAB LAP treatment reduced MDM cell viability to 39.4% 
compared to 83.7% in NMCAB-treated cells (P < 0.001). Based on the MDM toxicity 
profile, 100 µM was selected for following cell culture studies.  
3.4.5 MDM uptake and retention 
NMCAB was readily taken up by MDM and intracellular concentration increased over 
time to 146 nmoles/106 cells at 24 hours (Figure 3.12, uptake), which was 60- and 88-fold 
higher than CAB LAP and NCAB (2.4 nmoles and 1.6 nmoles/106 cells, respectively). In 
retention study (Figure 3.12, retention), NMCAB was retained within the cells for up to 
30 days, however CAB levels were not detectable in NCAB and CAB LAP-treated cells 
	
Figure 3.11	Toxicity evaluation in MDM.	Cell viability of MDM was assessed 8 hours after 
NMCAB or CAB LAP treatment over a concentration range of 0-400 µM. Results are shown 
as percentage of cell viability as compared to untreated MDM. Data are represent mean ± SD 
for n = 3 samples per group. Comparisons between NMCAB and CAB LAP were performed 
by Student’s t test. *** P < 0.001. 
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after 1 or 5 days. Both MCAB and CAB were detected in NMCAB-treated cells indicating 
that MCAB was hydrolyzed inside cells to release the CAB.  
To cross validate uptake and retention result, TEM was applied to visualize retained 
nanoparticles. We observed crystalline structures inside cell compartments of NMCAB-
treated MDM after 8 hours of drug loading, but importantly not in replicate cells treated 
with CAB LAP (Figure 3.13, uptake). After a 48-hour washout period, crystals remained 
	
Figure 3.12	NMCAB uptake and retention in MDM. CAB LAP and NCAB prepared using 
identical excipient and condition as NMCAB were used as assay controls. For uptake, 
intracellular drug concentrations were determined in MDM receiving 100 µM NMCAB, 
NCAB or CAB LAP treatment for 2-24 hours. Drug retention in MDM was determined after 
an 8-hour drug loading followed by washing and culturing with fresh media for additional 1-
30 days. Intracellular drug concentrations were analyzed by HPLC-UV/Vis. Both MCAB 
(dashed lines) and CAB (solid lines) were measured independently for NMCAB treated cells. 
Data are expressed as mean ± SD for n = 3 samples per group. 
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in NMCAB-treated MDM (Figure 3.13, retention), confirming that NMCAB crystals 
remain stable in cytoplasmic organelles for extended time periods. 
3.4.6 In vitro antiretroviral activity 
To investigate whether improvement in uptake and retention of NMCAB could 
translate into enhanced antiretroviral efficacy, MDM were treated with NMCAB, NCAB, 
or CAB LAP for 8 hours, followed by HIV-1ADA challenge (multiplicity of infection of 0.1 
infectious virus/cell) at days 0, 2, 5, 10, and 15. Enhanced antiretroviral activity was 
observed in cells treated with NMCAB compared to CAB LAP or NCAB. Media HIV RT 
	
Figure 3.13	Transmission electron microscopy (TEM) images of formulation-loaded MDM. 
MDM were imaged after 8 hours incubation with CAB LAP or NMCAB containing 100 µM 
of drug (Uptake). Drug crystals were observed only in NMCAB treated MDM. Retained 
crystals in NMCAB treated MDM were observed after a wash-off period of 48 hours 
(Retention). Scale bar: 2 µm. 
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activity in NMCAB-treated cells was significantly lower than that of CAB LAP and NCAB 
treated cells (Figure 3.14 A). For CAB LAP or NCAB treated cells, RT activity was 
	
Figure 3.14	NMCAB antiretroviral efficacy. MDM were treated with NMCAB, CAB LAP or 
NCAB containing 100 µM drug for 8 hours. At days 0, 2, 5, 10, and 15 post drug loading, 
MDM were challenged with HIV-1ADA at 0.1 MOI for 4 hours. Uninfected cells without 
treatment served as negative controls (Control); HIV-1 infected cells without any treatment 
served as positive controls (HIV-1). Samples were collected for antiretroviral activity test 
seven days after viral challenge. (A) HIV RT activities were measured in culture media. 
Results are shown as percentage of RT activities as compared to HIV-1 infected MDM. Data 
are expressed as mean ± SD for n = 6 samples per group. (B) Cells were fixed in 
paraformaldehyde and stained for HIV-1p24 antigen (brown). Scale bar: 100 µm. 
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suppressed only within the first two days of treatment, followed by increases in RT activity 
to 70 and 84% of the HIV-1 infected control at day 15, respectively. In contrast, sustained 
viral inhibition was observed in NMCAB-treated cells for up to 15 days. These findings 
were confirmed by HIV-1p24 staining, where no brown positive cells were detected up to 
10 days, with rare infected cells seen at day 15 in NMCAB-treated MDM. In contrast, for 
both CAB LAP and NCAB treatments HIV-1p24 positive cells were readily observed at 
day 0 challenge time point and increased to a level similar to HIV-1 positive control at 
subsequent time points (Figure 3.14 B). These data paralleled the rapid washout of CAB 
LAP and NCAB from the cells compared to sustained NMCAB crystals.  
3.5 Discussion 
As discussed in Chapter I and II, the era of LA ART has now emerged and LA regimens 
will soon become available [7, 18]. Nevertheless, they most likely will have a specific 
niche due, in part, to limitations associated with large injection volumes, injection site 
reactions, suboptimal dosing intervals, and lack of mucosal penetration [19, 20]. Apparent 
means to overcome these limitations rest with decreasing required injection volumes, 
broadening of dosing intervals, and targeting viral reservoirs. This is where we believe 
LASER ART can occupy this important niche.  
In Chapter II, we described macrophage targeted ART delivery using FA as targeting 
ligand. FA NCAB exhibited improvement in macrophage uptake, which translated into 
prolonged t1/2 in BALB/cJ mice. The resultant nanocrystal formulation was optimized in 
manufacturing process to guarantee the reproducibility and scalability. However, with 
more than 20 approved antiretroviral drugs in North America and Europe [21], only a few 
can be translated into LA regimens due to the compound intrinsic properties. That is where 
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chemical modification can fill the niche. The possibility for achieving enhanced viral 
reservoir entry, retention and long-term efficient release was recently demonstrated for 
abacavir (ABC) and lamivudine (3TC) [22, 23]. MCAB, like modifications in ABC and 
3TC, was designed to be cleaved in the presence of esterases, and to release native drug as 
well as myristic acid. Notably, myristic acid also has antiretroviral activity through 
inhibition of N-myristoyltransferase, an enzyme that affects the myristoylation of the viral 
life cycle related proteins [24-27]. CAB is metabolized by uridine diphosphate 
glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral 
drugs [28, 29]. Esterification on hydroxyl group may further reduce metabolism to achieve 
prolonged dosing interval. 
Amphiphilic P407 surfactant was used to stabilize NMCAB nanosuspensions. 
Lipophilic MCAB interacts with the hydrophobic core of the polymer to produce 
homogeneous surfactant coated nanocrystals. The formulation process of NMCAB was 
optimized to maximize drug loading with limited excipient usage, while maintaining 
scalability and long-term storage stability. This could potentially translate into reduced 
dosing volumes and decreased excipient-related adverse effects. In fact, a significantly 
higher reduction (P < 0.001) in MDM cell viability was observed upon treatment with 400 
µM CAB equivalents of CAB LAP as compared to NMCAB (Figure 3.11).  We believe 
this is due to the higher amount of excipients, especially surfactant, in the CAB LAP 
formulation [28]. NMCAB formulation has comparable particle size, polydispersity, and 
morphology as CAB LAP formulation. Previous studies have shown that particle 
morphology plays an important role in nanoparticle attachment and internalization by 
macrophages [16, 17]. Both NMCAB and CAB LAP exhibited rod shape morphology 
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(Figure 3.9), the preferred geometry for macrophage uptake. However, because of the 
intrinsic properties of CAB, it does not retain in macrophages. Both CAB LAB and NCAB 
formulation treated MDM exhibited drug concentration decline after 4 hours of treatment 
(Figure 3.12). NMCAB crystals retained in MDM for prolonged period of time, which is 
most likely due to the increased lipophilicity. Cellular retention is particular important for 
prevention as shown in Figure 3.14, only NMCAB treatment can protect MDM from HIV 
infection for prolonged time. 
3.6 Conclusions 
In summary, NMCAB, a nanoformulated prodrug of CAB, has been successfully 
developed with appreciable stability and scalability. It exhibits enhanced cellular entry and 
retention, and forms intracellular drug depots that provide sustained and effective drug 
release and long-term protection against HIV challenge in macrophages. 
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NMCAB pharmacokinetic and antiretroviral 




As mentioned in chapter III, CAB was chemically modified and nanoformulated into 
NMCAB, aiming to improve macrophage cellular retention. NMCAB exhibited extended 
retention with improved antiretroviral efficacy in MDM. Whether these in vitro 
improvements could translate into improved PK, BD, and antiretroviral efficacy in vivo 
have to be tested with animal models. In this chapter, PK studies in BALB/cJ mice 
demonstrated a 4-fold increase in half-life as compared to CAB LAP formulation, which 
was further confirmed by rhesus macaque PK study where up to 5 months sustained plasma 
drug concentrations were observed. Short-term PK study and injection site TEM analysis 
demonstrated that the reticuloendothelial system and local infiltrated immune cells play 
important roles in NMCAB redistribution, and are responsible for the prolonged half-life. 
The results coupled with improved viral restriction in human adult lymphocyte 
reconstituted NOD/SCID/IL2Rγc-/- mice led us to conclude that NMCAB can improve BD 
and viral clearance profiles upon current CAB LAP formulation.  
4.2. Introduction 
Despite all the promising profiles for CAB LAP as mentioned in previous chapters, the 
dosing pattern is still suboptimal. Recently, in a phase 2a study investigating safety and 
tolerability of CAB LAP in HIV-uninfected men (ECLAIR; NCT02076178) [1], 800 mg 
doses every 12 weeks was selected based on previous clinical studies [2, 3], aiming to 
maintain plasma CAB concentrations above 4× PA-IC90 (660 ng/mL), a concentration 
demonstrated to be protective against new infections in macaques [4-7]. However, two-
thirds of participants had faster than anticipated drug absorption from the injection site 
leading to plasma drug concentrations below targeted concentration of 4× PA-IC90 at 12 
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weeks. Therefore, follow up studies to HPTN 083 (a study for pre-exposure prophylaxis 
(PrEP) in HIV-uninfected cisgender men and transgender women) will require shortened 
dosing intervals (600 mg in 3 mL injection volumes every 8 weeks) to achieve sufficient 
plasma drug concentration and effective protection. Therefore, means to further improve 
dosing interval beyond 12 weeks and reduce injection volumes could bring broader usage 
to such regimens [8]. 
For hydrophobic compounds formulated into nanoparticles, after intramuscular 
administration, the injection site serves as the primary drug depot, from where API is 
dissolved and eventually dispersed into blood stream. Because drug dissolution is often the 
rate-limiting step in systemic drug uptake from depot, particle size can be tuned to control 
drug release rate. Macrophage targeted LA ART utilizes macrophage as additional drug 
depot and therefore could reduce Cmax while prolong t1/2 [9-11]. If NMCAB could achieve 
such PK improvements in animal models will be discussed in this chapter as compared to 
CAB LAP.  
As discussed in Chapter III, NMCAB was avidly taken up by macrophages and 
exhibited prolonged cellular retention. These properties enable NMCAB nanoparticles to 
be stored and transported by macrophages. In other words, macrophages serve as drug 
delivery vehicle for NMCAB. In this chapter, we tested if the improvements in vitro could 
translate into improved in vivo profiles including prolonged dosing interval and improved 
antiretroviral efficacy.  
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4.3. Materials and Methods 
4.3.1 Materials 
Paraformaldehyde (PFA), and 3,3’-diaminobenzidine (DAB) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Optima grade LC/MS water and ACN were 
purchased from ThermoFisher Scientific (Waltham, MA, USA). FITC mouse anti-human 
CD45, Alexa Fluor 700 mouse anti-human CD3, APC mouse anti-human CD4, and BV421 
mouse anti-human CD8 were purchased from BD Biosciences (San Jose, CA, USA). 
NMCAB was prepared as described in Chapter III, 3.3.6. CAB LAP formulation was a 
kindly gift provided by ViiV Healthcare (Research Triangle Park, NC, USA). 
4.3.2 PK and BD of NMCAB in BALB/cJ mice 
Male BALB/cJ mice (Jackson Labs, Bar Harbor, ME, USA) were administered 
intramuscularly with NMCAB or CAB LAP at dosage of 15 or 45 mg CAB equivalents/kg, 
followed by weekly blood collection in heparinized tubes via cheek bleeding. Plasma was 
collected via centrifugation at 2,000 × g for 5 min for the drug quantitation by ultra-
performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). At day 
28 and day 58 after nanoformulation injection, 5 mice in each treatment group were 
sacrificed and tissues including liver, lung, spleen, lymph node were collected for drug 
quantitation by UPLC-MS/MS. Time course plasma CAB concentrations were analyzed 
for non-compartmental PK parameters using WinNonlin-5.1 (Certara USA, Inc., Princeton, 
NJ, USA). 
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4.3.3 Short-term PK and BD evaluation 
To identify potential tissue depots for NMCAB, PK at early time points was assessed 
in male BALB/cJ mice after a single intramuscular injection of NMCAB or CAB LAP (45 
mg CAB equivalents /kg). At predetermined time points (15 min, 1, 2, 4, and 8 hours and 
1, 3, 7, 10 and 14 days), 25 µL of whole blood was collected and levels of both CAB and 
MCAB were determined. Tissues were collected at days 1, 3, 7 and 14 for drug quantitation 
by UPLC-MS/MS. 
4.3.4 UPLC-MS/MS plasma and tissue drug quantitation  
A Waters ACQUITY H-class UPLC (Waters, Milford, MA, USA) connected to a Xevo 
TQ-S micro mass spectrometer was used for UPLC-MS/MS analysis. For plasma/blood 
drug quantitation, 25 µL of sample was added into 1 mL ACN, followed by addition of 10 
µL internal standard (IS) solution to obtain a final concentration of 50 ng/ml.  d3-
dolutegravir (d3-DTG) and myristoylated dolutegravir (MDTG) were used as ISs for CAB 
and MCAB analysis, respectively. Samples were vortexed then centrifuged at 17,000 × g 
for 10 min. Supernatants were collected and dried using a ThermoScientific Savant Speed 
Vacuum (ThermoScientific, MA, USA) and reconstituted in 100 µL of 50% v/v ACN in 
Optima grade water; 10 µL was injected for CAB and MCAB UPLC–MS/MS analysis. 
Standard ACN were prepared in blank mouse plasma/blood in the range of 0.2-2000 ng/mL 
for CAB and MCAB. For tissue sample preparation, 15-200 mg of sample was 
homogenized in 4-19 volumes of 90% ACN in Optima-grade water using a TissueLyzer II 
(Qiagen, Valencia, CA, USA). ACN (80 µL), 50% ACN in water (10 µL), and IS (10 µL) 
were added to 100 µL of tissue homogenate, followed by vortexing for 3 min and 
centrifugation at 17,000 × g for 10 min. The supernatant (100 µL) was mixed with 50 µL 
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of Optima grade water for sample injection. Standards were prepared similarly using blank 
tissue homogenates with 10 µL of spiking solution (CAB/MCAB, 5-20,000 ng/mL in 50% 
ACN). For CAB quantitation, chromatographic separation of 10 µL CAB sample was 
achieved on an ACQUITY UPLC BEH Shield RP18 column (1.7 µm, 2.1 mm x 100 mm) 
using a 7-min gradient of mobile phase A (7.5 mM ammonium formate in Optima grade 
water, adjusted to pH 3 using formic acid) and mobile phase B (100% Optima grade ACN) 
at a flow rate of 0.25 mL/min. The initial mobile phase composition was 35% B for the 
first 3.5 min and was increased to 95% B in 0.5 min and held constant for 1.5 min. Mobile 
phase B was then reset to 35% in 0.5 min and the column was equilibrated for 1 min before 
the next injection. For MCAB quantitation chromatographic separation was achieved with 
a different 7-min gradient method at a flow rate of 0.35 mL/min. The initial mobile phase 
composition was 80% B for the first 4.5 min, and increased to 95% B in 0.25 min, held 
constant for 1 min, reset to 80% in 0.25 min and the column was equilibrated for 1 min 
before the next injection. CAB and MCAB were detected at a cone voltage of 10 V and 24 
V, respectively, and a collision energy of 24 V and 18 V, respectively, in the positive 
ionization mode. Multiple reaction monitoring (MRM) transitions used for CAB, MCAB, 
d3-DTG, and MDTG were 406.04 > 126.93, 616.28 > 406.09, 422.84 > 129.99, and 630.20 > 
420.07, respectively. Spectra were analyzed and quantified by MassLynx software version 
4.1. All drug concentrations were determined using analyte peak area to internal standard 
peak area ratios. 
4.3.5 Injection depot evaluation by TEM 
Muscle tissue from BALB/cJ mice at sites of injection were imaged by TEM. Twenty-
four hours after an intramuscular injection of NMCAB or CAB LAP at 45 mg CAB 
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equivalents /kg, mice were sacrificed and muscle tissues at the site of injection were 
dissected into 1-2 mm3 cubes for TEM sample processing. Tissue samples were fixed and 
processed for TEM image with the same processing method for cells as described in 
Chapter III, 3.3.10. 
4.3.6 Studies of viral restriction in HIV infected mice model 
Male 6-8-week-old NOD/SCID/IL2Rγc-/- (NSG) mice (Jackson Labs, Bar Harbor, ME, 
USA) were injected intramuscularly with NMCAB or CAB LAP at 45 mg CAB 
equivalents/kg. Eleven days after nanoformulation treatments, mice were reconstituted by 
intraperitoneal injection with 25 × 106 human peripheral blood lymphocytes (PBL) 
obtained by leukapheresis and centrifugal elutriation. Eleven days after reconstitution, 
mice were challenged with 104 50% tissue culture infectious dose (TCID50) HIV-1ADA by 
intraperitoneal injections. Mice were sacrificed 10 days after viral challenge. The 
experimental timeline is shown in	Figure 4.1. Peripheral blood was collected into Ca2+-
ethylenediaminetetraacetic acid (EDTA)-coated tubes at days 10 (before PBL 
reconstitution), 21 (before HIV-1 challenge), and 32 (10 days after HIV-1 challenge) for 
flow cytometry analysis of human pan-CD45, CD3, CD4 and CD8 immune markers [12]. 
Plasma was collected via centrifugation at 2,000 × g for 5 min at days 10, 21, and 32 for 
drug quantitation by UPLC-MS/MS. At the day of sacrifice, liver, spleen, lung, lymph 
nodes, bone marrow, gut, brain, and kidney were collected for drug quantitation by UPLC-
MS/MS.  
4.3.7 Viral load and HIV RNA and DNA PCR determinations 
HIV-1 viral load was analyzed in day 32 plasma samples using the Roche Amplicor 
and Taqman-48 system with HIV-1 kit V 2.0 according to the manufacturer’s instructions 
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(Roche Diagnostics, Indianapolis, USA). At the day of sacrifice, liver, spleen, lung, lymph 
nodes, gut, brain, and kidney were collected for viral RNA and DNA quantitation by semi-
nested real-time PCR [13], and immunohistochemical staining for HIV-1p24 antigen as 
described previously [14]. 
4.3.8 NMCAB PK in rhesus macaques 
Two male Chinese rhesus macaques (PrimeGen; 3 years old; 4.0 and 4.7 kg) were 
anesthetized with 10 mg/kg ketamine and injected intramuscularly with NMCAB at 45 mg 
CAB equivalents/kg in 2.1 and 2.5 mL, respectively. NMCAB was manufactured by the 
Nebraska Nanomedicine Production Plant Good Laboratory Practices (GLP) laboratory. 
Blood was collected into potassium EDTA tubes before administration, and at days 4, 7, 
11, and 18 after the administration, and biweekly thereafter. Plasma was obtained for 
metabolic panels and drug quantitation by UPLC-MS/MS. Peripheral blood mononuclear 
cells (PBMCs) were also obtained for complete blood counts. These were performed by 
the Nebraska Medical Center Pathology and Microbiology laboratory. Time course plasma 
CAB concentrations were analyzed for non-compartmental PK parameters using 
WinNonlin-5.1 (Certara USA, Inc., Princeton, NJ, USA). 
4.3.9 Nanomedicine Production Plant GLP Facility Production of NMCAB  
NMCAB formulation for rhesus macaque PK study was manufactured in a GLP 
Facility. The Operational Unit was responsible for following approved protocols and 
standard operating procedures (SOPs). All of the equipment followed strict protocols for 
calibration and cleaning before and after use. A witness verified all procedures performed 
in the GLP facility and every step was initialed and dated by the operator and verifier. The 
operator and verifier followed specific protocols for Personal Protective Equipment (PPE) 
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and behavior once in the GLP facility. This is a restricted access facility. Due to the 
importance and quality of work being done only Nebraska Nanomedicine Production Plant 
employees are granted access. All steps of the approved protocol were documented during 
manufacturing.  
The Quality Assurance Unit was responsible for monitoring this study to assure that 
the facilities, equipment, personnel, methods, practices, records, and controls were in 
conformance with the regulations. The Quality Assurance Unit is entirely separate from 
and independent of the personnel engaged in the direction and conduct of the study. They 
also maintained a copy of the master schedule sheet, copies of all protocols and determined 
that no deviations from approved protocols or standard operating procedures were made 
without proper authorization and documentation. 
The balances used two weight standards (10 gram and 200 gram) for calibration checks. 
All pipets had been calibrated. The Malvern Zetasizer Nano ZSP, which is used for size, 
polydispersity index and zeta potential measurements, used a 60 nm standard to check 
calibration. These steps were done before each use.  
Equipment such as the Avestin Emulsiflex C3 High Pressure Homogenizer have 
cleaning protocols which were implemented before and after use. The homogenizer had at 
least 500 mL of methanol, then sodium hydroxide and lastly 1500 mL of Water For 
Injection (WFI) circulated through it before and after each manufacturing run. The 
removable parts of the homogenizer were placed in the oven to bake at 200 ˚C for at least 
60 min. All of the glassware was also baked at 200˚ C for 60 min to remove pyrogens. The 
homogenizer had 40 mL of WFI run through it once it had been cleaned. A sample of this 
WFI was then tested for endotoxins with the Lonza Limulus Amebocyte Lysate 
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PRYOGEN-500 test kit to verify that the cleaning procedure was successful. This process 
was also carried out prior to using the homogenizer to verify no growth of any endotoxin 
between uses.  
4.3.10 Statistics 
Data were presented as mean ± standard error of the mean (SEM), each group contained 
5 (PK studies) or 8 (viral restriction study) mice. For comparison of two groups, Student’s 
t test (two-tailed) was used. For comparison among three groups, one-way ANOVA 
followed by Tukey’s or Dunnett T3 post hoc test was used based on the homogeneity of 
the samples. No outliers from animal or cell experiments were excluded. P < 0.05 was 
considered to be significant (*P < 0.05; **P < 0.01; ***P < 0.001). All the data were 
analyzed using GraphPad Prism 6.0 software (La Jolla, CA, USA) or IBM SPSS (Armonk, 
NY, USA). 
4.3.11 Study approval 
Human PBL were isolated by leukopheresis from HIV-1/2 and hepatitis seronegative 
donors according to an approved UNMC IRB exempt protocol. All animal studies were 
approved by the University of Nebraska Medical Center Institutional Animal Care and Use 
Committee in accordance with the standards incorporated in the Guide for the Care and 




4.4.1 NMCAB PK and BD analysis in BALB/cJ mice 
Male BALB/cJ mice were intramuscularly administered 15 or 45 mg CAB 
equivalents/kg of NMCAB or CAB LAP to assess PK and BD profiles for 8 weeks, the 
study timeline is shown in Figure 4.1. NMCAB treatment showed lower initial plasma 
drug concentrations 
but a slower CAB 
decay rate compared 
to CAB LAP 
treatment (Figure 
4.2). Compared to 
CAB LAP treated 
mice, NMCAB 
treatment achieved 
greater plasma drug 
concentration starting from day 21 and day 28 for 15 and 45 mg/kg dosage respectively. 
For 45 mg CAB equivalents/kg dosage groups, single injection of NMCAB provided CAB 
plasma drug concentrations beyond 4× PA-IC90 [24] for up to two months. At day 56, 
average plasma CAB concentration was 780 ng/mL in NMCAB treated mice. In contrast, 
plasma CAB concentrations in mice treated with CAB LAP fell below 4× PA-IC90 by day 
35 (Figure 4.2 B). For lower dose of 15 mg CAB equivalents/kg (Figure 4.2 A), NMCAB 
treatment maintained plasma CAB concentrations above 4× PA-IC90 for 28 days, which 
equals to what CAB LAP treatment could achieve with a 45 mg/kg dose.  
	
Figure 4.1 NMCAB PK and BD study experimental timeline. 
BALB/cJ mice were administered intramuscularly with 15 or 45 
mg/kg CAB equivalent of CAB LAP or NMCAB at day 0 followed 
by weekly blood collection to day 56. Mice were sacrificed at day 28 
and 56 respectively for tissue drug concentration determination. 
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 Non-compartmental PK parameters were calculated for plasma drug concentrations 
obtained from 45 mg/kg dosage groups (Table 4.1). The apparent terminal phase half-life	
(t1/2) after NMCAB intramuscular administration was 4-fold greater than for CAB LAP 
Parameters 
Treatment 
CAB LAP NMCAB 
λZ (1/days) 0.233 ± 0.004 0.060 ± 0.001 
t1/2 (days) 2.97 ± 0.05 11.58 ± 0.25 
AUClast (h*ng/mL) 6883997.7 ± 511013.4 6584058.1 ± 247768.7 
AUC0-∞ (h*ng/mL) 6884479.4 ± 511007.1 6897132.5 ± 260736.5 
AUC % Extrapolation 0.01 ± 0.00 4.53 ± 0.35 
Vβ /F (L/kg) 0.69 ± 0.06 2.64 ± 0.13 
	
Figure 4.2	NMCAB PK evaluation in BALB/cJ mice. Mice were administered intramuscularly 
with (A) 15 or (B) 45 mg/kg CAB equivalent of CAB LAP or NMCAB. Plasma was collected 
weekly for CAB concentration determination by UPLC/MS/MS. Horizontal dotted and dashed 
lines represent 1× and 4× PA-IC90 of CAB, respectively. Data represent mean ± SEM for n = 5 
mice per group and were compared by multiple t test. * P < 0.05, ** P < 0.01, *** P < 0.001. 
Data are expressed as mean ± SEM (n = 5). 
Table 4.1 BALB/cJ mice noncompartmental PK analysis	
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(11.6 compared to 3.0 days). Similarly, CAB mean residence time (MRT) was 2-fold 
longer for NMCAB compared to CAB LAP. The extended t1/2 of NMCAB was the result 
of a 4-fold increase in volume of distribution (Vβ/F), whereas clearance (CL/F) was 
comparable between all tested formulations. CAB LAP treated mice showed shorter t1/2 as 
compared to that was observed in FA NCAB PK study (Table 2.2) presumably because of 
the influence of FA deficient diet on the metabolic profiles. 
CAB concentrations in tissues including liver, spleen, lung, lymph node, etc. were 
illustrated in Figure 4.3 for 45 mg/kg dosage groups at both day 28 and 56. Significant 
greater drug concentrations were observed in all tested tissues in NMCAB treated animals 
	
Figure 4.3	NMCAB biodistribution. BALB/cJ mice were administered intramuscularly with 45 
mg/kg CAB equivalent of CAB LAP or NMCAB. Tissues were collected at day 28 (upper 
panel) and 56 (lower panel) post administration for CAB concentration determination by 
UPLC/MS/MS. LN: lymph node. Data are expressed as mean ± SEM for n = 5 mice per group. 
* P < 0.05, ** P < 0.01, *** P < 0.001 by Student’s t test. 
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as compared to CAB LAP treated ones. Assuming tissue density is 1 g/mL, NMCAB 
treatment provided tissue CAB concentrations above PA-IC90 (166 ng/mL) for all the 
tissues including lung, lymph node, kidney, gut and spleen, except for liver and brain 28 
days after initial injection. In contrast, for CAB LAP treated mice, drug concentrations 
were below PA-IC90 in all of the tested tissues. At day 56, tissue drug concentrations in 
CAB LAP treated mice were close to or below the detection limit. In contrast, significantly 
higher drug levels in NMCAB treated mice were detected. Notably, CAB concentration 
was still above PA-IC90 in lungs.  
4.4.2 Short-term PK evaluation for drug depot 
Unlike the high CAB concentrations at later time points, NMCAB treatment resulted 
in lower initial plasma CAB concentration as compared to CAB LAP. For example, day 7 
after 45 mg/kg drug administration, plasma CAB concentrations were 15,185 ng/mL in 
NMCAB treated mice versus 26,678 ng/mL in CAB LAP treated ones (P = 0.0089) (Figure 
4.2 B). This suggests a secondary depot and/or a slower release of the drug from injection 
depot. Therefore, a PK and BD study in BALB/cJ mice focusing on initial distribution of 
both MCAB and CAB was conducted to identify the potential tissue depot for the NMCAB 
formulation. After an intramuscular injection of 45 mg CAB equivalents/kg NMCAB 
formulation, MCAB exhibited fast distribution into blood stream providing blood MCAB 
concentration of 1,300 ng/mL at 15 min. However, blood MCAB dropped below 200 
ng/mL at two hours suggesting that MCAB was readily cleaved in blood (Figure 4.4, 
Blood). Twenty-four hours after injection, blood MCAB concentration was only 35 ng/mL, 
however in tissues, MCAB concentrations were much greater than the blood MCAB 
concentration. Notably, spleen (2,369 ng/g), liver (1,358 ng/g) and gut (908 ng/g) exhibited 
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highest MCAB concentrations at 24 hours (Figure 4.4). Lymph nodes exhibited a slower 
distribution, the highest MCAB concentration (2,057 ng/g) was observed at 72 hours after 
injection.  
4.4.3 Site of injection TEM analysis 
Injection site depots were analyzed by TEM to investigated the underlying mechanism 
of drug distribution after intramuscular injection (Figure 4.5). One day after injection, 
robust immune cell infiltration into injection site muscle was observed in BALB/cJ mice 
treated with NMCAB. The immune cells, including neutrophils and macrophages, were 
	
Figure 4.4	NMCAB short-term PK and BD evaluation. Tissue drug depot analysis. Time course 
of whole blood and tissue drug levels in BALB/cJ mice receiving a single intramuscular 
injection of NMCAB or CAB LAP at 45 mg CAB equivalents/kg for early time points up to 14 
days. Both CAB (solid lines) and MCAB (dashed lines) were measured in NMCAB treated 
mice. Horizontal dotted and dashed lines represent 1× and 4× PA-IC90, respectively. Data are 
expressed as mean ± SEM for n = 5 mice per group. 
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inside the muscle bundles (M) carrying substantial drug crystals (arrows) in the cytoplasm. 
	
	
Figure 4.5	Injection site depot analysis. BALB/cJ mice received intramuscular injection 
of CAB LAP or NMCAB were sacrificed 24 hours after drug administration. Injection 
site muscles were collected and analyzed by TEM. Representative figures of muscle 
cross-sections are shown. The muscle bundles are depicted as “M”; arrows point drug 
crystals. 
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In contrast, only a few immune cells were recruited for CAB LAP  injected muscle, and 
they were not actively taking up the drug crystals. As shown in Figure 4.5 lower panel, 
majority of drug observed drug crystals were not inside immune cells, instead they were 
between the muscle bundles.  
4.4.4 Viral restriction evaluation 
To determine whether the improved PK and BD profiles of NMCAB could translate 
into improved antiretroviral efficacy, NSG mice were administered a single intramuscular 
injection of NMCAB or CAB LAP at 45 mg CAB equivalents/kg on day 0, followed by 
human PBL reconstitution on day 11, challenge with HIV-1ADA on day 22, and necropsy 
10 days after HIV-1 challenge (Figure 4.6 A). Blood, plasma, and tissues were collected 
to determine drug levels, CD4/CD8 ratio, HIV-1p24 expression, viral load, and viral 
RNA/DNA.  
Flow cytometry analysis of human CD4+/CD8+ ratio at day 21 before HIV challenge 
demonstrated a successful establishment of human T cell system in the mice model (Figure 
4.6 B). 10 days after HIV-1ADA challenge, CD4+/CD8+ ratio dropped dramatically in mice 
received no treatment, while both NMCAB and CAB LAP treatment protected the animals 
from HIV-induced CD4+ T cell loss (Figure 4.6 B). Plasma viral load test demonstrated 
that NMCAB treatment provided superior viral restriction compared to CAB LAP 
treatment. Plasma viral load was not detectable in 2/8 animals in the NMCAB treatment 
group. The average viral load in the remaining 6 animals was 1.1×103 copies/mL as 
compared to 2.3×106 copies/mL in untreated HIV-1 controls and 3.7×105 copies/mL in 
CAB LAP pre-treated animals, respectively (Figure 4.6 C).  
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4.4.5 Tissue viral RNA and DNA evaluation 
At day 32 (10 days after viral challenge), tissues were collected for viral RNA and 
DNA quantitation by semi-nested real-time PCR. In all tissues, including spleen, lung, 
lymph node, and bone marrow, NMCAB treatment reduced viral RNA and DNA levels by 
over an order of magnitude, and in many tissues, levels were reduced over 3 logs10 
compared to HIV-1 positive controls or CAB LAP treated CAB LAP treated mice (Figure 
4.7). Notably, out of the 8 mice in NMCAB treatment group, viral RNA was below the 
	
Figure 4.6	Viral restriction of NMCAB compared to CAB LAP in hu-PBL reconstituted NSG 
mice. (A) Experimental timeline. NSG mice were treated intramuscularly with NMCAB or 
CAB LAP (45 mg CAB equivalents/kg) at day 0, followed by hu-PBL reconstitution at day 11, 
HIV-1ADA challenge at day 22, then sacrifice at day 32. (B) Peripheral blood CD4/CD8 T-cell 
ratios at days 21 and 32 were analyzed by flow cytometry. Data represent mean ± SEM (n = 8) 
and were compared by one-way ANOVA followed by Holm-Sidak post hoc test. * P < 0.05, ** 
P < 0.01, *** P < 0.001. 
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limit of detection in 1 animal for spleen, 3 for lymph node, 3 for lung, 6 for bone marrow, 
5 for liver, 8 for gut, 7 for brain, 4 for kidney (Figure 4.7 A); viral DNA was below the 
	
Figure 4.7 Tissues collected at day 32 were tested for (A) Viral RNA and (B) DNA by semi-
nested real time PCR. Values are presented as nucleic acid viral copies per 106 human CD45+ 
cells. LN: lymph node; BM: bone marrow. Open symbols represent samples that were below 
the detection limit. Data represent mean ± SEM (n = 8) and were compared by one-way 
ANOVA followed by Dunnett T3 post hoc test. * P < 0.05, ** P < 0.01, *** P < 0.001. 
	 102 
limit of detection in 6 mice for spleen, 8 for lymph node, 5 for lung, 6 for bone marrow, 7 
for liver, 8 for gut, 3 for brain, and 3 for kidney (Figure 4.7 B).  
PCR result was further confirmed by immunohistochemical analysis in spleen and lung 
(Figure 4.8). 7/8 animals in the NMCAB treated group were HIV-1p24 negative in spleen 
and 8/8 in lung, while HIV-1p24 positive cells were observed in all the CAB LAP treated 
	
Figure 4.8 HIV-1p24 staining for viral restriction study. NSG mice were treated 
intramuscularly with NMCAB or CAB LAP (45 mg CAB equivalents/kg) at day 0, followed by 
hu-PBL reconstitution at day 11, HIV-1ADA challenge at day 22, then sacrifice at day 32. Levels 
of HLA-DR and HIV-1p24 antigen in spleen and lung of human PBL-reconstituted NSG mice 
treated with NMCAB, CAB LAP, and HIV-1 control mice 10 days after HIV-1 challenge. Right 
panels are the cell counting from 5 views on each slide. Data represent mean ± SEM (n = 8) and 
were compared by one-way ANOVA followed by Tukey post hoc test. *** P < 0.001. 
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mice and untreated HIV-1 control animals. Representative images and quantitation of 
HLA-DR and HIV-1p24 staining are shown in Figure 4.8.	 
4.4.6 Plasma and tissue drug concentrations 
Plasma CAB concentrations were above the 4× PA-IC90 throughout the entire study in 
the NMCAB treatment group, whereas CAB LAP treatment failed to maintain plasma CAB 
concentrations above 4× PA-IC90 by the end of the study (Figure 4.9 A). Greater CAB 
concentrations were observed in all tested tissues including liver, spleen, lung, lymph nodes, 
kidney, gut, and brain. for NMCAB treated animals as compared to CAB LAP treated ones. 
This explains the improved viral restriction in the tissues. Notably, Pearson correlation 
analysis revealed a strong negative correlation between plasma CAB concentration and 
log10 plasma viral load (Figure 4.10) on day 32, highlighting the importance of maintaining 
sufficient drug concentrations to achieve ideal viral suppression.  
	
Figure 4.9 Viral restriction study animal plasma and tissue CAB concentrations. (A) Plasma 
CAB concentrations were detected on days 10, 21, and 32. Horizontal dashed line represents 
4× PA-IC90. Data represent mean ± SEM (n = 8) and were compared by multiple t test. (B) CAB 
concentrations in tissues were detected in NMCAB or CAB LAP treated mice on day 32. Data 
represent mean ± SEM (n = 8) and were compared by Student’s t test. * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
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4.4.7 Preliminary PK study in 
rhesus macaques 
A preliminary NMCAB PK 
study in non-human primates has 
supported our findings in rodents. 
Plasma CAB concentrations were at 
or above PA-IC90 for up to 158 
days in two male rhesus macaques 
given a single intramuscular 
injection of NMCAB at 45 mg CAB 
equivalents/kg (Figure 4.11). 
Plasma CAB concentrations 
	
Figure 4.10	 Correlation between plasma CAB 
concentrations and log10 plasma viral load on day 32 in 
drug treated mice was computed. Pearson correlation 
coefficient (r) = -0.875, P < 0.0001. 
	
Figure 4.10 NMCAB PK study in rhesus macaques.	Two Chinese rhesus macaques were 
administered intramuscularly with 45 mg CAB equivalents/kg NMCAB. Plasma CAB and 
MCAB concentrations were monitored up to 172 days. Horizontal dotted and dashed lines 
represent 1× and 4× PA-IC90 of CAB, respectively. 
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reached a maximum at day 7 and were maintained afterwards with slow decline rate. This 
is in contrast to previous studies on the PK of CAB LAP in male rhesus macaques, which 
showed that 10 weeks after a 50 mg/kg intramuscular dose, plasma CAB concentrations 
were below the PA-IC90 for all the animals with relatively fast decay [4]. Calculated PK 
parameters (Table 4.2) demonstrated a prolonged t1/2 of 22.5 and 23.8 days, respectively 
for each monkey, which is approximately 2-4 fold as compared to previous reported t1/2 
(5-12 days) for CAB LAP in male macaques. Consistent with PK data in BALB/cJ mice, 
MCAB levels were negligible as compared to CAB level in monkeys as well indicating a 
fast prodrug cleavage in blood. Complete blood counts (CBC) and metabolic profiles were 
unchanged before and after NMCAB treatment (Table 4.3). 
Table 4.2 Rhesus macaque non-compartmental PK analysis 
PK Parameters Monkey 1 Monkey 2 Average 
λZ (1/day) 0.0254 0.0308 0.0281 
t1/2 (day) 27.2 22.5 24.9 
AUClast (day*ng/mL) 60661.6 74987.4 67824.5 
AUC0-∞ (day*ng/mL) 65959.9 82096.9 74028.2 
AUC % Extrapulation 8.0 8.7 8.3 
Vβ /F (L/kg) 26.8 17.8 22.3 
CL/F (L/day/kg) 0.68 0.55 0.62 





Table 4.3	Complete blood counts and metabolic panel of rhesus macaques administrated 
with NMCAB 
Monkey 1    Days     
Parameters 0 4 7 11 18 25 32 46 
WBC Count (×106/µL) 10.8 10 10.7 11.7 8.6 11.1 11 10 
RBC Count (×106/µL) 4.97 4.72 4.64 4.54 4.48 4.79 4.91 4.93 
Hemoglobin (g/dL) 12.1 11.5 11.2 11 10.9 11.7 11.9 12 
Hematocrit (%) 36.5 36.1 33.3 34.3 33.3 36.3 37.3 37.8 
MCV (fL) 73.4 76.5 71.8 75.6 74.3 75.8 76 76.7 
MCHC (%) 33.2 31.9 33.6 32.1 32.7 32.2 31.9 31.7 
RBC Distrib Width  (%) 15.2 14.6 15.1 15.5 16.1 15.4 15.7 14.8 
Platelet Count (×103/µL) 363 374 448 446 351 374 397 353 
Neutrophil Seg (%) 8 6 18 10 10 9 18 15 
Neutrophil Band (%) 0 0 0 1 0 0 0 0 
Lymphocyte (%) 80 91 80 85 84 81 78 84 
Monocyte (%) 11 2 2 3 5 9 3 0 
Eosinophil (%) 1 1 0 1 1 1 1 1 
Basophil (%) 0 0 0 0 0 0 0 0 
Nucleated RBC (/diff) 0 0 0 0 0 0 0 0 
Absolute Neutrophil (×103/µL) 0.9 0.6 1.9 1.3 0.9 1 2 1.5 
Absolute Lymphocyte (×103/µL) 8.6 9.1 8.6 9.9 7.2 9 8.6 8.4 
Absolute Monocyte (×103/µL) 1.2 0.2 0.2 0.4 0.4 1 0.3 0 
Absolute EOS (×103/µL) 0.1 0.1 0 0.1 0.1 0.1 0.1 0.1 
Absolute BASO (×103/µL) 0 0 0 0 0 0 0 0 
AST (U/L) 25 50 32 31 31 27 32 28 
Alkaline Phosphatase (U/L) 810 624 654 584 639 668 637 674 
Bilirubin Total (mg/dL) 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 
Calcium (mg/dL) 10.2 9.7 10 10 10 10 10.2 10.3 
Protein Total (g/dL) 6.8 6.4 6.4 6.5 3.1 6.7 6.8 6.6 
Albumin (g/dL) 4.5 4 4.1 4.3 4.3 4.5 4.7 4.5 
Glucose/Random (mg/dL) 101 92 74 77 52 77 82 69 
Urea Nitrogen (mg/dL) 21 23 20 22 21 21 22 21 
Creatinine (mg/dL) 0.56 0.54 0.5 0.51 0.53 0.49 0.55 0.54 
Bun/ Creatinine Ratio 
(mgUN/mgCR) 
37.5 42.6 40 43.1 39.6 42.9 40 38.9 
Sodium (mmol/L) 145 145 144 144 146 144 146 146 
Potassium   (mmol/L) 3.2 3.5 3.8 3.6 3.3 3.7 3.3 3.8 
Chloride (mmol/L) 107 104 106 105 105 106 106 108 
Osmolality / Calc (mOsm/kg) 302 302 298 299 301 298 303 302 
Carbon Dioxide  (mmol/L) 16 18 23 23 24 21 19 23 
Anion Gap (mmol/L) 22 23 15 16 17 17 21 15 
ALT (U/L) 53 90 78 60 35 37 36 47 
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Monkey 2    Days     
Parameters 0 4 7 11 18 25 32 46 
WBC Count (×106/µL) 3.4 6 3.4 5.7 5.5 4 3.8 4.5 
RBC Count (×106/µL) 4.92 4.92 4.69 4.57 4.68 4.6 4.56 5.02 
Hemoglobin (g/dL) 11.8 11.8 11.3 11 11.4 11 10.8 12 
Hematocrit (%) 35.8 37.8 33.5 34.5 34.8 34.8 35 38.6 
MCV (fL) 72.8 76.8 71.4 75.5 74.4 75.7 76.8 76.6 
MCHC (%) 33 31.2 33.7 31.9 32.8 31.6 30.9 31.1 
RBC Distrib Width (%) 12 11.9 12.3 12.4 12.7 12.4 12.7 12.3 
Platelet Count (×103/µL) 342 358 372 401 372 330 367 326 
Neutrophil Seg (%) 26 35 32 32 48 31 24 30 
Neutrophil Band (%) 0 0 0 1 0 0 0 1 
Lymphocyte (%) 72 60 62 57 47 63 68 56 
Monocyte (%) 2 3 5 5 0 5 8 3 
Eosinophil (%) 0 2 1 5 5 1 0 10 
Basophil (%) 0 0 0 0 0 0 0 0 
Nucleated RBC (/diff) 0 0 0 0 0 0 0 0 
Absolute Neutrophil (×103/µL) 0.9 2.1 1.1 1.9 2.6 1.2 0.9 1.4 
Absolute Lymphocyte (×103/µL) 2.4 3.6 2.1 3.2 2.6 2.5 2.6 2.5 
Absolute Monocyte (×103/µL) 0.1 0.2 0.2 0.3 0 0.2 0.3 0.1 
Absolute EOS (×103/µL) 0 0.1 0 0.3 0.3 0 0 0.5 
Absolute BASO (×103/µL) 0 0 0 0 0 0 0 0 
AST (U/L) 48 54 35 33 34 27 36 30 
Alkaline Phosphatase (U/L) 339 311 317 286 296 302 296 271 
Bilirubin Total (mg/dL) 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.3 
Calcium (mg/dL) 9.9 9.5 9.7 9.7 9.8 9.8 9.9 9.8 
Protein Total (g/dL) 7 7.1 6.7 6.9 7.2 7.3 7.2 6.9 
Albumin (g/dL) 4.4 4.1 4 4.1 4.4 4.3 4.5 4.2 
Glucose/Random (mg/dL) 65 88 66 95 88 81 69 87 
Urea Nitrogen (mg/dL) 23 23 22 21 21 19 21 23 
Creatinine (mg/dL) 0.53 0.57 0.54 0.56 0.64 0.57 0.65 0.68 
Bun/ Creatinine Ratio 
(mgUN/mgCR) 43.4 40.4 40.7 37.5 32.8 33.3 32.3 33.8 
Sodium (mmol/L) 144 143 143 144 144 143 145 145 
Potassium (mmol/L) 4 3.4 3.8 3.5 2.9 3.8 3.3 3.6 
Chloride (mmol/L) 104 102 103 102 101 103 104 104 
Osmolality / Calc (mOsm/kg) 298 298 296 299 299 296 300 302 
Carbon Dioxide (mmol/L) 18 15 27 26 21 25 22 25 
Anion Gap (mmol/L) 22 26 13 16 22 15 19 16 
ALT (U/L) 36 57 56 52 36 32 31 42 
         





As discussed in Chapter IV, NMCAB was designed to improve macrophage entry and 
retention and ultimately improve PK profiles. This could potentially address the limitations 
of the first generation LA ART in terms of large injection volume, injection site reaction, 
suboptimal dosing intervals, lack of tissue penetration [8, 15, 16]. In this Chapter, 
NMCAB’s ability to improve CAB PK profile was tested in both mice and monkeys. 
NMCAB exhibited prolonged t1/2 in both mice and monkey PK studies as compared to that 
has been reported for CAB LAP formulation. It is notable in rhesus macaque PK study that 
plasma drug concentration was above or close to 1× PA-IC90 for up to 5 months after 45 
mg/kg administration. This is in contrast with previous reported monkey PK profile of 
CAB LAP that the plasma CAB concentration fell below 1× PA-IC90 at 10 weeks after 
intramuscular injection of 50 mg/kg CAB LAP [4].  
In clinical trials, monthly to bimonthly dosing is readily achievable for CAB LAP due 
to the drug’s extended half-life, high protein binding capacity, and slow dissolution rate [3, 
16, 17]. The long half-life of CAB after intramuscular injection is primarily due to the slow 
release of the drug from injection site depots. This is notable and observed in animal studies 
at muscle site depots. In contrast, such drug depots were not observed in replicate animals 
injected with NMCAB. Instead, abundant numbers of immune cells, including 
macrophages and neutrophils, appeared at the site of injection carrying drug crystals in 
cytoplasmic organelles after injection (Figure 4.5). These findings suggested a fast cell 
entry and redistribution of the NMCAB nanoparticles. After cell entry, NMCAB undergoes 
slow dissolution to release the prodrug that is readily hydrolyzed back into active CAB. 
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The change of major drug depot from muscle injection site to cells and tissues may also 
reduce injection site reactions. It is important to note that myristic acid lipophile on MCAB 
can facilitate cell penetration and enhanced long term nanocrystal stability. 
MCAB was instantly cleaved back into CAB in blood as negligible MCAB was 
detected in the short-term PK study. In contrast, high MCAB concentrations were observed 
in certain tissues such as spleen, lymph node, liver and gut (Figure 4.4), suggesting that 
reticuloendothelial system plays a critical role in NMCAB redistribution and those tissues 
may serve as secondary depot for NMCAB particles. The mechanisms for extended half-
life of NMCAB rests in structural properties that facilitate drug cellular entry and retention. 
Another potential mechanism is reduced drug metabolism by blocking of its hydroxyl 
group through esterification. Altogether, in mice NMCAB treatment provided a 4 times 
longer half-life than CAB LAP with reduced peak concentrations, reflecting a slower 
release of the drug from depots [2]. With lower carboxylesterase activity and a slower 
metabolic rate in humans compared to mice [18, 19], NMCAB could extend dosing 
intervals beyond two months and reduce overall dosage.  
CAB LAP has been demonstrated to be highly protective against viral challenge in non-
human primates irrespective of route of infection [4-7]. In our comparisons of viral 
restriction, we used human PBL-reconstituted NSG mice as a screening tool. While plasma 
CAB concentrations were above 4× PA-IC90 throughout the study, HIV infection was, 
nonetheless, still observed. We posit that this was due to several aspects of this mouse 
model. First is xenoreactivity. In human PBL-reconstituted mice, engraftment of mature 
human lymphocytes commonly leads to graft-versus-host effects. This enables human 
lymphocyte activation and an increased susceptibility to HIV-1 infection [20]. Second is a 
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high rate of available viral target cells. Human CD4+ T cell percentage after reconstitution 
was 52% of total CD3+ cells providing a large pool of host cells. Third is the high dose of 
administered HIV-1. 104 TCID50 was used to infect PBL-reconstituted mice. Under these 
circumstances, CAB LAP could not achieve protection against HIV challenge as it has 
achieved in rhesus macaques [4-7]. Nonetheless, the enhanced susceptibility to HIV 
challenge in this model provided a “proof of concept tool” to compare NMCAB and CAB 
LAP. It is noteworthy that NMCAB treated animals showed significantly lower plasma and 
tissue viral loads as compared to CAB LAP treated mice. These improvements are based 
on its ability to maintain plasma drug levels above 4× PA-IC90 for prolonged time beyond 
what CAB LAP can provide. Future studies using more comprehensive humanized mouse 
model and SHIV challenge in rhesus macaques will provide more information on 
NMCAB’s ability to prevent new infections. 
4.6 Conclusion 
 Rodent and rhesus macaque PK, distribution, and viral restriction evaluations revealed 
that NMCAB is able to extend dosing intervals, enhance tissue drug concentrations, and 
improve antiretroviral profiles beyond the current CAB LAP formulation. Fast cellular 
entry and redistribution of NMCAB as the result of chemical modification facilitate 
secondary depot formation in cells and tissues. 
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Chapter V 




The very first combinational LA ART, CAB plus RPV, will soon become available [1], 
which will likely bring revolutionary changes in HIV/AIDS therapy and prevention. 
Prolonged dosing intervals and reduced overall dosage presumably improve patient 
adherence and treatment satisfaction with better restricted viral replication and mutation [2, 
3]. Nevertheless, there are still remaining issues including injection volumes, injection site 
reactions, suboptimal dosing intervals, and limited viral reservoir penetration [4-6]. This 
research project has proposed solutions for above-mentioned limitations by macrophage-
targeted delivery based on nanomedicine and medicinal and polymer chemistry strategies. 
Based on previous studies in our laboratory [7], FA was incorporated into CAB 
nanoparticles to target FA receptors expressed on activated macrophages [8]. The 
formulation process has been optimized to guarantee reproducibility and scalability. 
Particularly, purification process was considered to be essential to remove excess FA 
polymer that competes FA nanoparticle receptor binding [7]. Nevertheless, the purification 
procedure is time-consuming, and even particle damaging. Therefore, in this project, we 
optimized the manufacturing process and were able to eliminate the troublesome 
purification steps to achieve stable, high loading, reproducible and scalable FA decorated 
CAB formulation. One improvement of current FA NCAB formulation is the usage of 
limited amount of polymer that is precisely determined by NMR analysis of purified 
formulations. Another improvement lies in the usage of 100% FA-P407 polymer instead 
of the mixture of P407 and FA-P407. This ensures that the particle surfaces are occupied 
exclusively by targeted polymer, so that polymer exchanges would not affect the targeting 
ability. The optimized formulation exhibited enhanced macrophage uptake and improved 
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PK profiles. It is important to mention this manufacturing strategy is not only limited to 
FA NCAB. It may also apply to hydrophobic API and nanocrystal formulations with or 
without targeting ligand. 
To further improve CAB delivery, particularly to improve cellular retention of CAB, 
chemical modifications had to be applied based on our observations that all CAB 
formulations with or without targeting ligand were retained in MDM only for a short time. 
To address this problem, myristoyl CAB has been synthesized to improve CAB’s 
lipophilicity. This could potentially improve PK profile and API’s penetration into tissues. 
The resultant MCAB showed favorable physicochemical properties with negligible 
changes in antiretroviral activity. After the chemical modification and nanoformulation 
process, cellular retention in MDM was significantly extended to up to 30 days. Notably, 
the retained drug crystals successfully protected MDM from HIV challenge for prolonged 
time.  
Translational potential of NMCAB was then tested in multiple animal models. 
NMCAB achieved extended half-life and improved tissue drug concentrations from mice 
PK studies. With lower carboxylesterase activity and a slower metabolic rate in humans 
compared to mice [9, 10], NMCAB could extend dosing intervals beyond two months and 
reduce overall dosage. These were confirmed, in part, by PK evaluations of NMCAB in 
rhesus macaques, where sustained effective plasma drug concentration was observed for 
up to 5 months after single intramuscular injection. Viral restriction study in hu-PBL 
reconstructed mice model confirmed that the favorable PK profile and improved tissue 
drug concentration could ultimately lead to enhanced antiretroviral activity. 
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Taken together, this project has the potential to improve LA ART delivery through 
targeting and medicinal chemistry strategies. The resultant FA NCAB and NMCAB could 
both address current LA ART issues of suboptimal dosing intervals and lack of drug 
delivery to viral reservoirs. In addition, this project provides a universal means to simplify 
manufacturing processes of nanocrystal formulations that enables appreciable formulation 
stability and scalability for translational applications. We believe these improvements will 
positively affect outcomes of HIV treatment and prevention. 
5.2 Challenges and future directions 
Current project has provided improvements beyond LA ART that are currently under 
development. Further improvement can be achieved by combining ligand-targeted delivery 
and prodrug strategies. Preliminary study in our laboratory has demonstrated that 
incorporation of FA on the NMCAB nanoparticle could further improve macrophage 
uptake (data not shown). Other targeting ligands that target macrophages or CD4 positive 
cells, such as hyaluronic acid [11], tuftsin [12], gp120 peptide [13], etc., are also being 
tested. From chemistry perspective, prodrug can be further optimized using different 
lipophilic moieties. Another key factor for CAB cellular retention is the lipophilic moiety 
for the chemical modification. Various fatty acid chains are being tested for optimal 
cellular entry and retention. Another preliminary study indicated that 18-carbon stearic acid 
modified CAB exhibited greater MDM uptake than NMCAB (data not shown).  
One challenge in developing LA ART regimens is to further ease the administration 
and to restrict the injection site adverse effects. Discovery of novel highly potent 
antiretroviral drugs to lower the overall administration dosage is one path. Alternatively, 
formulation strategies, such as co-formulation of multiple drugs in a single injection 
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volume, reduction of unnecessary excipient usage as proposed in current project, could 
further reduce required injections each time and excipient-associated toxicities for broad 
application. Another concern for LA ART is that once injected, the regimen cannot be 
removed, which could potentially expose patients to intractable adverse effects. One 
solution is the usage of oral lead-in regimens of the same drugs as currently applied in 
clinical trials [1]. Development of retrievable LA ART implants will also provide solution. 
Nevertheless, current retrievable implants in development requires surgical procedures, 
even if minor, to insert or retrieve the implantable agents [14], which could be a concern 
for the patients and may need additional infrastructure. Therefore, retrievable LA ART that 
can be easily administered could further broad the application of LA ART. Taken together, 
while the dosing pattern change from daily oral administration to monthly/bimonthly 
injection could potentially address patient adherence problems, next generation LA ART 
regimens that can further simplify administration, prolong dosing intervals, reduce long-
term toxicities, and can retrieve after injection could help to better fight against HIV/AIDS. 
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